



XXXIInd EDITION

04 > 06.03.20

HILTON HOTEL ANTWERPEN



www.bwge.be

daflon[®] 500 GEMICRONISEERD

Voor de behandeling van hemorroiden

Publieke prijs (= ten laste van de patiënt)

180 tabletten	€ 48,87
120 tabletten	€ 35,98
90 tabletten	€ 30,72
60 tabletten	€ 22,75
30 tabletten	€ 14,23

POSOLOGIE HEMORROIDEN:



NAAM VAN HET GENEESMIDDEL: Daflon 500 mg filmomhulde tabletten. **KWALITATIEVE EN KWANTITATIEVE SAMENSTELLING:** Gemicroniseerde gezuiverde flavonoidfractie (500 mg), die 450 mg diosmine en 50 mg in hesperidine uitgedrukte flavonoiden bevat. Voor de volledige lijst van hulpstoffen, zie SPK. **FARMACEUTISCHE VORM:** Ovale, zalmkleurige filmomhulde tabletten. **THERAPEUTISCHE INDICATIES:** - Behandeling van verschijnselen van functionele of organische chronische veneuze insufficiëntie van de onderste ledematen: zwaartegevoel, pijn, nachtelijke krampen, oedeem, trofische stoornissen. Behandeling van de acute crisis van de hemorroidale ziekte, voorgesteld als onderhoudsbehandeling van functionele en objectieve verschijnselen van hemorroidaal lijden. **DOSERING EN WIJZE VAN TOEDIENING:** **Dosering:** Veneuze ziekte: Gebruikelijke dosis: 2 tabletten per dag in één inname of 2 verschillende innames, bij de maaltijd. **Hemorroidale ziekte:** **Acute crisis:** 6 tabletten per dag gedurende de 4 eerste dagen, dan 4 tabletten per dag gedurende 3 dagen. **Onderhoudsbehandeling:** 2 tabletten per dag. **Wijze van toediening:** Oraal gebruik. **CONTRA-INDICATIES:** Overgevoeligheid voor het actieve bestanddeel of voor één van de hulpstoffen in het product. **BIJZONDERE WAARSCHUWINGEN EN VOORZORGEN BIJ GEBRUIK:** De behandeling met venotropea mag niet langer dan 3 maanden duren zonder een herevaluatie van de symptomatologie. De toediening van dit product als symptomatische behandeling van een hemorroidale crisis sluit een specifieke behandeling van andere anale ziekten niet uit. Indien de symptomen niet vlug verdwijnen, moet er een protocolologisch onderzoek worden uitgevoerd en de behandeling worden herzien. **INTERACTIES:** Tot nu toe zijn er geen interacties met andere geneesmiddelen gemeld. **ZWANGERSCHAP EN BORSTVOEDING:** **Uit voorzorg heeft het de voorkeur het gebruik van Daflon 500 mg te vermijden tijdens de zwangerschap. Het is niet bekend of het actief bestanddeel/metabolieten in de moedermelk wordt uitgescheiden. Risico voor pasgeborenen/zuigelingen kan niet worden uitgesloten. Er moet worden besloten of borstvoeding moet worden gestaakt of er moet worden gestopt met/afgezien van de behandeling met Daflon 500 mg, rekening houdend met het voordeel van borstvoeding voor het kind en met het voordeel van de behandeling voor de vrouw. **VRUCHTBAARHEID** BEÏNVLOEDING VAN DE RIJVAARDIGHEID EN VAN HET VERMOGEN OM MACHINES TE BEDIENEN** BIJWERKINGEN:** Samenvatting van het veiligheidsprofiel: de bijwerkingen gemeld met Daflon tijdens de klinische studies zijn gematigd. Het zijn voornamelijk gastro-intestinale stoornissen (diarree, dyspepsie, misselijkheid, braken). De volgende bijwerkingen kunnen worden waargenomen en zijn geklasseerd volgens de volgende frequentie: zeer vaak ($\geq 1/10$); vaak ($\geq 1/100$, $< 1/10$); soms ($\geq 1/1000$, $< 1/100$); zelden ($\geq 1/10000$, $< 1/1000$); zeer zelden ($< 1/10000$); niet bekend (kan met de beschikbare gegevens niet worden bepaald). **Zenuwstelselaandoeningen:** **Zelden:** duizeligheid, cefalea, omgemarkt. **Maagdarmstelselaandoeningen:** **Vaak:** diarree, dyspepsie, misselijkheid, braken - **Soms:** colitis. - **Niet bekend:** buikpijn. **Huid- en onderhuidsaandoeningen:** **Zelden:** pruritus, rash, urticaria. - **Niet bekend:** geïsoleerd oedeem van het gezicht, de lippen, de oogleden. **Uitzonderlijk:** een Quincke-oedeem. **Post-marketing ervaring:** De melding van vermoedelijke bijwerkingen: Het is belangrijk om na toelating van het geneesmiddel vermoedelijke bijwerkingen te melden. Op deze wijze kan de verhouding tussen voordelen en risico's van het geneesmiddel voortdurend worden opgevolgd. Beroepsbeoefenaren in de gezondheidszorg wordt verzocht alle vermoedelijke bijwerkingen te melden via: België: Federaal agentschap voor geneesmiddelen en gezondheidsproducten – Afdeling Vigilantie – Postbus 97 - B-1000 Brussel Madou - Website: www.fagg.be - E-mail: adversedrugreactions@fagg-afmps.be - Luxembourg: Direction de la Santé - Division de la Pharmacie et des Médicaments - Allée Marconi - L-2120 Luxembourg - Tél: +352 2478 5592 - Fax: +352 2479 5615 - E-mail: pharmacovigilance@ms.etat.lu - Lien pour le formulaire: <http://www.sante.public.lu/fr/politique-sante/ministere-sante/div-pharmacie-medicaments/index.html> **OVERDOSERING:** ** Er is een beperkte ervaring met overdosering van Daflon. De meest frequent gemelde bijwerkingen in gevallen van overdosering zijn gastro-intestinale klachten (zoals diarree, misselijkheid, buikpijn) en huid-aandoeningen (zoals jeuk, huiduitslag). De behandeling van een overdosis moet bestaan uit het behandelen van de klinische symptomen. **FARMACODYNAMISCHE EIGENSCHAPPEN:** Venotonicum en vasculoprotector. Daflon 500 mg werkt in op het vasculaire terugstromingssysteem; ter hoogte van de venen vermindert het de veneuze uitzetbaarheid en verlaagt het de veneuze stase, ter hoogte van de microcirculatie normaliseert het de capillaire doorlaatbaarheid en verhoogt het de capillaire weerstand, ter hoogte van de lymfe verhoogt het het lymfedebiet. **VERPAKKING:** Dozen van 30, 36, 60, 90, 120 en multiverpakking van 180 (2 dozen van 90). **HOUDER VAN DE VERGUNNING VOOR HET IN DE HANDEL BRENGEN:** SERVIER BENELUX N.V., Internationalelaan 57 - 1070 Brussel, België. **NUMMER VAN DE VERGUNNING VOOR HET IN DE HANDEL BRENGEN:** België: BE145153; G.H. Luxemburg: 2008079860. **AFLERINGSWIJZE:** vrij. **DATUM VAN HERZIENING VAN DE TEKST:** Goedkeuringsdatum: 05/2019 **Voor de volledige informatie, zie SPK. BN DN NA 05 19 - Goedkeuringsdatum van de verkorte SPK: 10/10/2019. BN 20 DN 1 EU PP - Goedkeuringsdatum van de medische informatie: 10/10/2019.



WELCOME

Dear Colleagues,

It is our pleasure to welcome you to the XXXIIth Edition of the Belgian Week of Gastroenterology.

Enclosed you will find the complete program of this meeting. We are pleased we can offer you once again a variety of high-quality **scientific meetings** combining the presentation of **cutting-edge research** performed at our Belgian institutions as well as **state-of-the-art lectures** by renowned experts on a wide range of topics, relevant to our field and its various subdisciplines.

Besides these scientific sections that constitute the backbone of the congress for many years, the BWGE 2020 offers a lot of other attractive sessions and activities!

We kick-off on **Wednesday 4th March** with the second edition of the **BWGE Postgraduate Course**. The speakers of the PGC will focus on new diagnostic and therapeutic insights into a specific gastrointestinal disorder with direct impact on daily **clinical practice**. The program is oriented towards clinical gastroenterologists, fellows and trainees and is part of a 3-year postgraduate program covering all fields and updates in our specialty. This PGC hence fits well within the aim of the BWGE: bringing together clinicians and researchers in a stimulating meeting.

We also invite you to attend **the satellite symposia**, organized by some of our sponsors, featuring top-experts for exciting talks or panel discussions.

Posters will be permanently displayed on interactive screens in the exhibition hall. Some of the best posters will be discussed during lunchtime in a separate area in the exhibition hall. We encourage you to attend these sessions and support our young researchers.

This year's **ultrasound course** on Wednesday covers basic abdominal ultrasonography, with the possibility to train on healthy volunteers.

We also invite you to attend The **Belgian Society of Gastrointestinal Endoscopy live endoscopy** session, scheduled on Friday morning as part of the PGC, followed in the afternoon by the session of the **Working Group of Proctology**, offering again an exciting clinical program.

The **Young Belgian Association for the Study of the Liver** participates with a scientific session on Wednesday afternoon.

During the **Interactive Case Report Sessions** on Thursday and Friday morning, interesting and rare cases will be discussed and commented on.

Do not forget to join us for the **Welcome Drink on Wednesday** from 5:00 to 6:00pm in the Exhibition Area and **the Award Ceremony and Evening Party on Thursday evening at the Felix Pakhuis!!**

We hope you will enjoy a stimulating scientific meeting!



Sven **FRANCQUE** and Isabelle **COLLE**
Scientific Coordinators of the Belgian Week of Gastroenterology

All abstracts will be published in
Acta Gastroenterologica Belgica.

Acta Gastroenterologica is accessible on internet :
www.acta-gastroenterologica.be

Editor-in-Chief: Nicolas LANTHIER



INDEX

WELCOME	3
INDEX	4
GENERAL INFORMATION	6
STEERING COMMITTEE	7
SATELLITE SYMPOSIA	8
INVITED LECTURES	10

WEDNESDAY MARCH 04

Postgraduate Course	12
BIRD Basic	15
Welcome Drink	18
YOUNG BASL	19
ULTRA SOUND Course	20

THURSDAY MARCH 05

BASL	23
BIRD CLINICAL	33
BSGIE GUIDED e-POSTER TOUR	38
BSGIE	40
PROGRAM OVERVIEW	44-45
GIREM	46
BeSPGHAN	52
SHORT ORAL PRESENTATIONS OF THE BEST e-POSTERS: Basic Science	54
GRANTS & PRIZES	57
DINNER & PARTY	58

FRIDAY MARCH 06

BGDO	60
WORKING GROUP OF DIGESTIVE PATHOLOGY	64
BSGIE LIVE SESSION	66
INTERACTIVE CASE REPORT SESSION: Hepatobiliary diseases	68
BEST e-POSTERS CLINICAL FOR ORAL PRESENTATION	70
BELGIAN PANCREATIC CLUB	72
BELGIAN WORKING GROUP ON PROCTOLOGY	74
e-POSTERS	76
SAVE THE DATE	84



04 > 06.03.20

GENERAL INFORMATION

ACCREDITATION

CME credits will be provided by online submission to the registered delegates who have attended the sessions. The number of credits is 6 credits points per day (category 3). The file from the online accreditation registrations will be sent to the **INAMI/ RIZIV** end of April 2020.

LANGUAGES

Dutch, French and English. English (British spelling) for abstracts, slides and announcements.

As proposed at the Steering Committee of 1995, Belgian authors may present their original papers in their mother tongue.

VENUE

HILTON ANTWERPEN

Groenplaats, 32 - 2000 Antwerpen

Tel: +32 3 204 12 12

Website: www.antwerp.hilton.com

PARKING

Here are the closest parkings to the Hilton Antwerp : parking fees are the responsibility of the participants.

- Groenplaats Parking: The Hilton Antwerp has reserved 200 places for our congress.
- Meir Parking
- Brabo Parking
- Lombardia Parking

EVENT COORDINATOR / SCIENTIFIC SECRETARY

DME-EVENTS - ANNE-FRANCE DE MEYER

57 av. G. Demeylaan - 1160 Bruxelles / Brussel

Tel. +32 477 27 00 45

E-mail: anne.france.de.meyer@dme-events.eu

STEERING COMMITTEE

SCIENTIFIC COORDINATORS

Sven FRANCQUE - Isabelle COLLE

SCIENTIFIC SOCIETIES

VVGE

Vlaamse Vereniging voor Gastroenterologie
P. Caenepeel, I. Colle

SRBGE

Société Royale Belge de Gastroenterologie
C. Van Kemseke, G. Verset

BSGIE

Belgian Society of Gastrointestinal Endoscopy
R. Bisschops, C. Snauwaert, E. Toussaint

BASL

Belgian Association for the Study of the Liver
A. Geerts, S. Negrin-Dastis

BGDO

Belgian Group of Digestive Oncology
M. Peeters, A. Hendlisz

RBSS

Royal Belgian Society of Surgery
A. De Roover, J. Lerut

RESEARCH GROUPS

GIREM

Belgian Network on Gastrointestinal Regulatory
Mechanisms
I. Depoortere

Working Group of Digestive Pathology

A. Hoorens, A. Driessen

BESPGHAN

Belgian Society for Paediatric Gastroenterology
Hepatology and Nutrition
B. Hauser, P. Bontems

SBNC

Société Belge de Nutrition Clinique
A. Van Gossum

VVKVM

Vlaamse Vereniging voor Klinische Voeding en
Metabolism
D. Ysebaert

BIRD

Belgian IBD Research Club
J.F. Rahier, P. Hindryckx

BPC

Belgian Pancreatic Club
M. Delhay, P. Deprez

BHPSG

Belgian Microbiota and Helicobacter Study Group
V. Lamy, P. Bontems, F. Mana

BLIC

Belgian Liver Intestine Committee
O. Detry, J. Pirenne

Belnuc

Belgian Society of Nuclear Medicine
R. Hustinx, C. Deroose

Basic research groups

L. Van Grunsven

Belgian Working Group of Proctology

C. Van Kemseke, D. De Looze

Young BASL

R. Bielen, A. Putignano

Young VVGE

A. Van Hootegem

ABDOMINAL ULTRASOUND STUDY GROUP

J. Schouten, L. Vonghia

POSTGRADUATE COURSE

D. De Looze

SATELLITE SYMPOSIA

WEDNESDAY MARCH 04

- 15:30 - 16:00** **TAKEDA:**
The gut-selective mechanism of action of vedolizumab.
 Speaker: Sebastian Zeissig (Dresden, Germany)
- 17:00 - 17:45** **PFIZER**
Controlling Ulcerative Colitis in 2020: the doctors' and patients' perspectives.
 Speakers: Edouard Louis (CHU Liège) / Anneline Cremer (ULB Erasme)

THURSDAY MARCH 05

- 08:00 - 08:30** **EISAI/MSD**
REFLECTing on a new treatment in unresectable and/or advanced hepatocellular carcinoma.
 Speaker : Jeroen Dekervel (UZ Leuven)
- 10:00 - 10:30** **BAYER**
Decision making in the jungle of therapies for advanced HCC: an evidence-based approach.
 Speaker: Chris Verslype (UZ Leuven)
- 10:25 - 10:55** **BIOGEN**
BIOSIMILARS: A Fuel to Innovation.
 Speaker: Pieter Dewint (AZ Maria Middelaers, Gent / UZ Antwerpen)
- 12:30 - 13:15** **JANSSEN-CILAG**
Will Treat-to-Target with early endoscopic assessment lead to better outcomes?
 Speakers: Mark Löwenberg & Floris de Voogd (AMC Amsterdam, The Netherlands)
- 13:15 - 14:00** **GILEAD**
The Countdown towards HEP C Elimination has started!
 Chair: Marc Van Ranst (KU Leuven)
 Speakers: Stefan Bratovanov & Werner De Keyser (VZW Free Clinic Antwerp)
 Astrid Marot (CHU UCL Namur), Mike Cool (AZ Damiaan Oostende), Marie-Eve Janssen (MASS Liège), Tessa Windelinckx (GIG Coordinator), Wim Verlinden (AZ Nikolaas, Sint-Niklaas)
- 17:15 - 17:45** **ALNYLAM**
Unravel the cause of unexplained, severe abdominal pain.
 Speaker: David Cassiman (UZ Leuven)

FRIDAY MARCH 06

- 08:30 - 09:00** **ELI LILLY**
Lightning talks on aICC. Addressing the gaps & looking ahead.
 Ivan Borbath (UCL Saint-Luc), Jeroen Dekervel (UZ Leuven)

PERSONALIZED NURSING SERVICE@HOME



Free call:

NL: 0800/18.244

FR: 0800/99.608

Email: nex2youservice@iqvia.com



Free call:

NL: 0800/18.003

FR: 0800/18.005

Email: stivathomeservice@iqvia.com

* Nex2You: for patients receiving Sorafenib.
Stiv@Home: for patients receiving Regorafenib.

INVITED LECTURES

WEDNESDAY MARCH 04

Postgraduate Course :

See program Postgraduate Course p 12-13

BIRD :

Genes involved in gut homeostasis: focus on enterocytes.

Sebastian Zeissig (Technical University Dresden, Germany)

Early inflammatory and monogenic diseases.

Jean-Pierre Hugot (Hôpital Robert Debré, APHP, Paris, France)

Role of exosomal microRNAs in fibrotic disease.

Sébastien Njock (University of Liège)

Young BASL:

Different approaches to Hepato-Cellular Carcinoma diagnosis: from the molecular to the radiological perspective.

- Molecular Perspective. - Radiological Perspective.

Jean-Charles Nault (Jean Verdier Hospital - Inserm, Paris, France)

THURSDAY MARCH 05

BASL :

BELIAC Lecture: Pitfalls of bariatric surgery in NAFLD and liver transplant patients.

Anja Geerts (UZ Gent)

MARC HAUTEKEETE Lecture: Prediction of mortality in cirrhotic patients before surgery.

Rosa Martín Mateos (Hospital Ramón y Cajal, Madrid, Spain)

Brohée Lecture :

NASH, think outside the liver.

Isabelle Leclercq (UCL Saint-Luc)

BIRD :

Current evidence for dietary treatment in Crohn's disease.

Gigi Veereman (UZ Brussels)

How can telemedicine and patient empowerment improve IBD care in 2020?

Marieke Pierik (University of Maastricht, Netherlands)

How to do a tight monitoring in Crohn's disease: role of small bowel capsule endoscopy, entero-MRI and other morphologic explorations.

Arnaud Bourreille (University of Nantes, France)

GIREM:

Characterizing the development of coordinated activity in the human fetal gut neuromusculature.

Conor McCann (UCL Great Ormond Street Institute of Child Health, Stem Cells and Regenerative Medicine, London, UK)

The contribution of sodium channels to sensory perception in the gut.

Frank Bosmans (UGent)

The gut-liver axis in health and disease – prospects of understanding and targeting macrophages.

Alexander Wree (Berlin, Germany)

INVITED LECTURES

BSGIE:

Management of common bile duct stones.

Peter Meier (Hannover, Germany)

Endoscopic management of chronic pancreatitis.

A. Tringali (Roma, Italy)

BeSPGHAN:

On Boarding Improved Care Now for participating centers.

R. Colletti and Cincinnati team, USA

K. Shelley (Burlington, USA)

FRIDAY MARCH 06

Working Group of Digestive Pathology: Oesophagitis (non-Barrett).

A. Driessen (UZ Antwerpen)

Dysplasia and submucosal oesophageal lesions:

what Gastroenterologists want to know from pathologists?

D. Tate (UZ Gent)

Pathology of Barrett's oesophagus: from metaplasia to dysplasia and cancer.

M. Jansen (UCL, London, UK)

Standardized macroscopic examination for cancer of the oesophagus and esophagogastric junction.

L. Verset (ULB Bordet)

Diagnostic criteria and histopathological reporting of malignant epithelial oesophageal tumours.

P. Demetter (ULB Bordet)

Molecular pathology of oesophageal cancer and its clinical implications.

P. Pauwels (UZ Antwerpen)

BPC: Anatomic variations of the bilio-pancreatic ductal system and bilio-pancreatic diseases.

Myriam Delhaye (ULB Erasme Brussels)

New ESGE update on PEP prevention guidelines.

J.-M. Dumonceau (Hôpital Marie Curie, Charleroi)

BSGIE Live Transmission: Brief talk complication management in ERCP/EUS.

Pieter Meier (Hannover, Germany)

Proctology: Critical appraisal of (new) interventional techniques in hemorrhoidal disease.

L. Siproudhis (Rennes, France)

Postgraduate Course

TEUN/LIJN



8:30-10:10 - SESSION 1

Moderators : M. Delhaye (ULB Erasme),
H. Reynaert (UZ Brussel)

- **08:30** **Management of acute alcoholic hepatitis.**
C. Moreno (ULB)
- **08:55** **Treatment algorithm for hepatocellular carcinoma.**
H. Van Vlierberghe (UGent)
- **09:20** **How to manage pancreatic cysts? When are they benign?**
S. Van der Merwe (KULeuven)
- **09:45** **Early diagnosis of pancreatic cancer.**
J.-L. Van Laethem (ULB)

■ **10:10-10:40** COFFEE BREAK

10:40-12:20 - SESSION 2

Moderators : M. Delhaye (ULB Erasme),
H. Reynaert (UZ Brussel)

- **10:40** **Clinical management in chronic diarrhea.**
S. Kindt (VUB)
- **11:05** **Prevention of infections in IBD.**
J.-F. Rahier (UCL)
- **11:30** **Management of dysplasia in IBD.**
C. Reenaers (ULg)
- **11:55** **Metastasized colorectal cancer: therapeutic strategies.**
M. Peeters (UZAntwerpen)

■ **12:20-13:45** LUNCH



13:45-15:25 - SESSION 3

**Moderators : I. Colle (ASZ Aalst, UGent),
D. De Looze (UZ Gent)**

- **13:45** **Achalasia. What is the ideal long-term treatment?**
G. Boeckstaens (KULeuven)
- **14:10** **Therapy refractory reflux: what to do if PPI's fail?**
J. Tack (KULeuven)
- **14:35** **Helicobacter pylori in 2020... Still an issue?**
F. Mana (St Jean, BRX)
- **15:00** **Constipation: a practical approach.**
H. De Schepper (UZ Antwerpen)

■ 15:25 - 16:00 COFFEE BREAK

16:00-17:15 - SESSION 4

**Moderators : I. Colle (ASZ Aalst, UGent),
D. De Looze (UZ Gent)**

- **16:00** **Duodenal polyps: identification and management strategy.**
P. Deprez (UCL)
- **16:25** **Lower gastro-intestinal bleeding.**
C. Van Kemseke (ULg)
- **16:50** **Endoscopic polypectomy: hot or cold?**
D. Tate (UGent)
- **17:15** **End of the session**

Takeda Satellite Symposium

Wednesday 4th of March 2020

From 15.30-16.00



14:00-15:30 - SESSION 1 : IBD BASIC

Moderators : C. Reenaers (ULiège), D. Laukens (UZ Gent)

- 14:00 **Invited Lecture: Genes involved in gut homeostasis: focus on enterocytes.**
Sebastian Zeissig (Technical University Dresden, Germany)
- 14:25 I01 **Integrin expression changes on the T cell subsets influence the response to vedolizumab in inflammatory bowel disease patients.**
C. De Galan (1), S. Van Welden (1), S. Bos (1), S. Tavernier (1), T. Lobaton Ortega (1), G. Gonzales (1), W. Van Moerkercke (2), B. Strubbe (3), H. Peeters (3), E. Macken (4), M. De Vos (1), D. Laukens (1), P. Hindryckx (1) / [1] UZ Gent, [2] AZ Groeninge Hospital, Kortrijk, [3] AZ St Lucas, Ghent, [4] UZ Antwerpen
- 14:35 I02 **The interplay of microbiome dysbiosis and immune system deregulation in patients with Crohn's disease.**
N. Seyed Tabib, C. Caenepeel, K. Machiels, S. Verstockt, B. Verstockt, N. Ardeshtir Davani, J. Sabino, M. Ferrante, S. Vermeire / UZ Leuven
- 14:45 I03 **Exposure to an inflammatory mix re-induces inflammation in organoids of ulcerative colitis patients, independent of the inflammatory state of the tissue of origin.**
K. Arnauts, B. Verstockt, J. Sabino, S. Vermeire, C. Verfaillie, M. Ferrante / KU Leuven
- 14:55 I04 **Serum protein markers for early and differential IBD diagnosis validated by machine learning approaches.**
S. Verstockt (1), N. Verplaetse (1), D. Raimondi (1), B. Verstockt (1), E. Glorieus (2), M. De Decker (3), L. Hannes (1), V. Ballet (4), E. Vandeput (1), Y. Moreau (1), M. Ferrante (1), D. Laukens (2), F. Mana (3), M. De Vos (2), S. Vermeire (1), I. Cleynen (1) / [1] KU Leuven, [2] UZ Gent, [3] UZ Brussel, [4] UZ Leuven
- 15:05 **Invited Lecture: Early inflammatory and monogenic diseases.**
Jean-Pierre Hugot (Hôpital Robert Debré, APHP, Paris, France)

- 15:30-16:00 **Satellite Symposium TAKEDA:**
The gut-selective mechanism of action of vedolizumab.

Speaker: Sebastian Zeissig (Dresden, Germany)



- 16:00-16:15 **COFFEE BREAK**

16:15-17:10 - SESSION 2

Chairs : C. Liefferinckx (ULB Erasme),
M. Ferrante (KU Leuven)

- **16:15** I05 **A mucosal marker predicting tofacitinib induced endoscopic response in ulcerative colitis.**
B. Verstockt (1), S. Verstockt (2), D. Alsoud (2), J. Sabino (1), M. Ferrante (1), S. Vermeire (1) / [1] UZ Leuven, [2] TARGID, KU Leuven
- **16:25** I06 **SLC12A2 as a potential histological marker of ulcerative colitis associated colorectal dysplasia.**
A. Merli (1), S. Vieujeau (2), C. Massot (2), N. Bletard (2), F. Quesada Calvo (2), D. Baiwir (1), G. Mazzucchelli (1), L. Servais (1), O. Wéra (2), C. Oury (1), L. De Leval (3), C. Sempoux (3), M. Roberto (2), M. Scharl (4), G. Rogler (4), E. De Pauw (1), C. Coimbra Marques (2), A. Colard (5), A. Vijverman (6), P. Delvenne (2), M. Meuwis (2), E. Louis (2) / [1] ULg Liège, [2] CHU Liège, [3] CHUV Lausanne, Suisse, [4] University Hospital, Zurich, Switzerland, [5] CHC, Liège, [6] CHR La Citadelle
- **16:35** I07 **The gut microbiota during biological therapy for inflammatory bowel disease.**
C. Caenepeel (1), S. Vieira-Silva (1), B. Verstockt (1), K. Machiels (1), N. Davani (1), J. Sabino (2), M. Ferrante (2), J. Raes (2), S. Vermeire (2) / [1] KU Leuven, [2] UZ Leuven
- **16:45** **Invited Lecture: Role of exosomal microRNAs in fibrotic disease.**
Sébastien Njock (University of Liège)

-
- **17:00-17:45** **Satellite Symposium PFIZER:**
Controlling Ulcerative Colitis in 2020: the doctors' and patients' perspectives.
Speakers: Edouard Louis (CHU Liège) /
Anneline Cremer (ULB Erasme)
-



- **18:00-18:30** **General Assembly IBD-BIRD**



Gastroenterology

Putting the patient first

Controlling Ulcerative Colitis in 2020: the doctors' and patients' perspectives

Pfizer-Sponsored
Satellite Symposium at the



Satellite Symposium


Wednesday March 4, 2020

Timing: 17:00 – 17:45

32nd edition BWGE – 2020

Hilton Hotel Antwerp

Room TIFFANY/SHAH



Speakers

Edouard Louis, MD PhD

Head of the department of Gastroenterology, University Hospital Liège, Liège, Belgium

Anneline Cremer, MD

Medical Gastroenterology Department, Erasme Hospital, Brussels, Belgium

WELCOME DRINK

ROOM

BELLE ÉPOQUE
EXHIBITION AREA



WEDNESDAY 4TH

17:00 - 18:00



04 > 06.03.20

14:00-15:30 - SESSION 1

Moderators : S. Lefere (UZ Gent), E. Trepo (ULB Brussels)

Invited Lecture: Different approaches to Hepato-Cellular Carcinoma diagnosis: from the molecular to the radiological perspective.

■ 14:00

Molecular Perspective

Jean-Charles Nault (Jean Verdier Hospital - Inserm, Paris, France)

■ 14:45

Radiological Perspective

Martina Pezzullo (ULB Erasme, Brussels)

■ 15:30 - 16:00 COFFEE BREAK

16:00-17:25 - SESSION 2

Moderators : I. Mannaerts (VUB Brussels),
L. Vonghia (UZ Antwerpen)

MSD Best Clinical and Basic Publications 2019:

■ 16:00

Glycome Patterns of Perfusate in Livers Before Transplantation Associate With Primary Nonfunction.

Xavier Verhelst (UZ Gent)

■ 16:20

Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients with Severe Alcoholic Hepatitis.

Eric Trepo (ULB, Brussels)

■ 16:40

Invited Lecture - Starter Investigators: Contribution of gEnome-wide eXpression profiles to the Risk of hEpatocellular carcinoma (EXPLORE).

Lukas Otero-Sanchez (ULB, Brussels)

■ 16:55

Therapeutic potential of isoform-specific HIF-1 α and HIF-2 α antisense oligonucleotides in a hepatocellular carcinoma mouse model.

Bart Vanderborght (UZ Gent)

■ 17:10

Intestinal mucosal immunity in the pathogenesis of primary sclerosing cholangitis.

Lena Smets (KU Leuven)

■ 17:25

End of the Session

ULTRASOUND Course

ROOM:
FLORENTINE


17:00-19:00

Dear colleagues and friends,

This year, the BWGE organises once again a practical, hands on **session in ultrasound** on **Wednesday afternoon**.

The course will focus on general principles of **abdominal ultrasound, knobology and normal anatomy** (including gastrointestinal tract (appendix, stomach,...). The course aims at trainees in gastroenterology and general medicine with **little or no ultrasound experience**.

After a short theoretical introduction, **participants will be able to practice on healthy volunteers**. In the beginning of the session, participants will be divided according to their level of experience.



JOIN US IN... JOGGING / WALKING AGAINST IBD

Thursday 5 March 2020

- **Meeting Point**
Lobby of the Hilton, Groenplaats Antwerp
- **Time**
6.45 AM to start at 7 AM for a jogging or a walk
- **Charity**
50 € per participant is donated to



An initiative from



Putting the patient first

Sign up by February 15th, 2020 at www.bwge.be or simply register by using the link:
<http://www.bwge.be/jogging-birdpfizer/>

Belgian Week of Gastroenterology

32nd Edition

04 - 06.03.2020

HILTON Hotel Antwerp



Hold the date

EISAI/MSD Breakfast Symposium

REFLECTing on a new treatment
in unresectable and/or advanced
hepatocellular carcinoma.

Speaker: Prof. Jeroen Dekervel, UZ Leuven.

Thursday March 5

08.00 - 08.30

Room: TEUN

Breakfast will be served from 07.30



MSD



Date of preparation: January 2020
BE-LENA-19-00048

- **08:00-08:30** **Satellite Symposium Eisai/MSD**
REFLECTing on a new treatment in unresectable and/or advanced hepatocellular carcinoma.
 Speaker : Jeroen Dekervel (UZ Leuven)



08:30-10:00 - SESSION 1

**Moderators : J.-P. Mulkay (CHU Saint-Pierre),
D. Ysebaert (UZ Antwerpen)**

- **08:30 A01** **Safety and preliminary efficacy of human adult liver progenitor cells (HepaStem™) in patients with acute-on-chronic liver failure (ACLF) or acute decompensation (AD) at risk of developing ACLF.**
 F. Nevens (1), T. Gustot (2), P. Laterre (3), L. Lasser (4), L. Haralampiev (5), V. Vargas (6), D. Lyubomirova (7), A. Albillos (8), V. Barthel (9), N. Clerget-Chossat (9), E. Sokal (9) / [1] KU Leuven, [2] ULB Erasme, Brussels, [3] UCL Saint-Luc, Brussel, [4] CHU Brugmann, Brussels, [5] Hospital Medica Ruse, Bulgaria, [6] Hospital Vall d'Hebron, Barcelona, Spain, [7] University Multiprofile Hospital «Dr. Georgi Stranski», Pleven, Bulgaria, [8] Hospital Universitario Ramón y Cajal Catedrático de Medicina, Universidad de Alcalá, Madrid, Spain, [9] Promethera Biosciences, Mont-Saint-Guibert
- **08:40 A02** **Viral hepatitis in Belgian prisons: a first-time multicenter prevalence study.**
 D. Busschots (1), R. Bielen (1), Ö. Köc (1), E. Dercon (2), C. Brixko (3), P. Laukens (4), P. Bilaey (4), F. De Smet (4), G. Hellemans (4), G. Muyldermans (5), L. Van Baelen (5), H. Van Vierberghe (6), G. Robaey (1) / [1] Hasselt University, [2] zorGGroep Zin, Hasselt, [3] CHR La Citadelle, [4] Federale Overheidsdienst Justitie, Brussel, [5] Sciensano, Brussels, [6] UZ Gent
- **08:50 A03** **Hypoxia-induced angiogenesis protects the liver from small for size Syndrome.**
 A. Dili (1), M. De Rudder (2), B. Pirlot (2), L. Dewachter (3), C. Bertrand (1), C. Bouzin (2), I. Leclercq (2) / [1] CHU UCL Namur, [2] UCL, Brussels, [3] ULB, Brussels
- **09:00 A04** **18F-Fluorocholine and 18F-Fluorodesoxyglucose PET/CT for Clinical Staging of patients with Hepatocellular Carcinoma.**
 H. Couvert (1), R. Marechal (2), R. Moreno-Reyes (3), O. Vierasu (3), M. Pezzullo (3), A. Bucalau (3), G. Verset (3) / [1] ULB Faculty of Medicine, [2] CHU Tivoli, La Louvière, [3] ULB Erasme
- **09:10 A05** **Are liver inclusive intestinal grafts protected against rejection?**
 M. Clarysse, E. Canovai, L. Ceulemans, T. Vanuytsel, G. De Hertogh, D. Monbaliu, J. Pirenne / UZ Leuven

- 09:20 A06 **Prevalence and characteristics of cystic fibrosis-associated liver disease in a cohort of adult cystic fibrosis patients.**

Z. Issa, S. Gohy, B. Delire, G. Dahlqvist / UCL Saint-Luc

- 09:30-10:00 **Brohee lecture:**
NASH, think outside the liver.

Isabelle Leclercq (UCL Saint-Luc)

- 10:00-10:30 **Satellite Symposium BAYER:**
Decision making in the jungle of therapies for advanced HCC: an evidence-based approach.

Speaker: Chris Verslype (UZ Leuven)



- 10:30-10:45 **COFFEE BREAK**

- 10:45-11:15 **BELIAC Lecture:**
Moderator: Jacques Pirenne (UZ Leuven)
Pitfalls of bariatric surgery in NAFLD and liver transplant patients.
Anja Geerts (UZ Ghent)



BAYER Satellite Symposium

Thursday 05/03 10.00-10.30

**Decision making in
the *jungle* of therapies for
advanced HCC: an evidence
based approach**

Speaker:
Prof Chris Verslype,
UZ Leuven

Hilton Hotel, Antwerp - Room: TEUN

11:15-12:35 - SESSION 2

**Moderators : T. Vanwolleghem (UZ Antwerpen),
F. Nevens (UZ Leuven)**

- **11:15 A07 Plasma protein glycomics combined with circulating fragments of cytokeratin-18 are reliable biomarkers to diagnose alcoholic hepatitis.**
X. Verhelst (1), A. Geerts (1), L. Meuris (2), H. Degroote (1), M. Tanguy (3), H. Davy (3), T. Issoufaly (3), F. Durand (4), N. Callewaert (2), H. Van Vlierberghe (1), P. Rautou (4) / [1] UZ Gent, [2] VIB, Gent, [3] Inserm, Paris, France, [4] Hôpital Beaujon, Clichy, France
- **11:26 A08 Long-term outcome of symptomatic alcoholic hepatitis with a Maddrey discriminant function < 32.**
D. Degré (1), R. Stauber (2), G. Englebert (1), F. Sarocchi (2), L. Verset (5), F. Rainer (2), W. Spindelboeck (2), H. Njimi (6), E. Trépo (3), T. Gustot (1), C. Lackner (2), P. Deltenre (3), C. Moreno (3) / [1] CUB Erasme, Belgium, [2] Medical University of Graz, Austria, [5] ULB Bordet, Brussels, [6] ULB Brussels
- **11:37 A09 The link between the gut and the liver during early alcoholic liver disease.**
L. Maccioni (1), B. Pirlot (1), I. Leclercq (1), Y. Horsmans (2), B. Schnabl (3), P. Starkel (2) / [1] UCL Brussels, [2] UCL Saint-Luc, Brussels, [3] University of California San Diego, San Diego, USA
- **11:48 A10 Role of the gut microbiota in the modulation of the gut-liver-brain axis in alcohol use disorders: proof of concept with the fecal microbiota transplantation.**
S. Leclercq (1), T. Le Roy (1), S. Furgieue (2), V. Coste (1), L. Bindels (1), A. Neyrinck (1), C. Quoilin (1), C. Amadiou (1), V. Tagliatti (2), P. Cani (1), K. Verbeke (3), J. Colet (2), P. Stärkel (1), P. De Timary (1), N. Delzenne (1) / [1] UCL, Brussels, [2] UMONS, [3] KU Leuven
- **11:59 A11 Myosteatorsis is associated with early NASH in the context of obesity and metabolic syndrome.**
M. Nachit (1), G. Vande Velde (2), W. Kwanten (3), O. Schakman (1), J. Thissen (1), M. De Rudder (1), C. Bouzin (1), B. Op De Beeck (3), Y. Horsmans (8), L. Van Gaal (9), S. Francque (3), I. Leclercq (1) / [1] UCL, Brussels, [2] KU Leuven, [3] UZ Antwerpen, [4] UCL Saint-Luc, Brussels, [5] U Antwerpen

■ **12:10 A12 Hepatitis E Virus Genotype 3 subtype dependent clinical outcomes in Belgium 2010 – 2018.**

T. De Somer (1), M. Peeters (2), S. Klamer (2), F. Nevens (3), J. Delwaide (4), P. Stärkel (5), P. Willems (6), S. De Maeght (7), C. Moreno (8), M. Van Hoof (9), I. Colle (10), F. Sermon (11), C. Van Steenkiste (12), F. Janssens (13), J. Van Acker (14), A. Marot (15), E. Bottieau (16), M. Reynders (17), C. De Galocsy (18), L. Lasser (19), M. Steverlynck (20), J. Maus (21), W. Verlinden (22), A. Geerts (23), M. Gallant (24), S. Van Outryve (25), H. Reynaert (26), J. Mulkay (27), J. Decaestecker (28), V. Suin (2), S. Negrin-Dastis (29), S. Van Gucht (2), T. Vanwolleghem (1) / [1] UZ Antwerpen, [2] Sciensano, Brussels, [3] UZ Leuven, [4] CHU of Liège, [5] UCL Saint-Luc, Brussels, [6] Sint Augustinus Ziekenhuis GZA, Antwerp, [7] Centres Hospitaliers Jolimont, [8] ULB Erasme, Brussels, [9] Clinique Saint-Luc Bouge, Namur, [10] ASZ, Aalst, [11] OLV Aalst, [12] AZ Maria Middelaes, Gent, [13] Jessa Ziekenhuis, Hasselt, [14] AZ Sint-Lucas, Gent, [15] CHU UCL Namur, Yvoir, [16] Institute of Tropical Medicine Antwerp, [17] AZ Sint-Jan Brugge-Oostende, [18] Hôpitaux Iris Sud, Brussels, [19] CHU Brugmann, Brussels, [20] Centre Hospitalier Mouscron, [21] ZNA Middelheim, Antwerpen, [22] AZ Nikolaas, Sint-Niklaas, [23] UZ Gent, [24] Jan Yperman Hospital, Ieper, [25] GZA Sint-Vincentius ziekenhuis, Antwerpen, [26] UZ Brussel, [27] CHU Saint-Pierre, Brussels, [28] AZ Delta, Roeselare, [29] Grand Hôpital de Charleroi

■ **12:21 A13 Transcriptome profiling of liver biopsies before antiviral treatment start can predict HCC development 8.3 years before clinical diagnosis in chronic Hepatitis B and C patients.**

S. Van Hees (1), B. Cuypers (2), S. Bourgeois (3), K. Kreefft (4), D. Sprengers (5), G. Robaey (6), P. Meysman (2), L. Vonghia (1), P. Michiels (1), S. Francque (1), R. De Man (4), A. Driessen (1), A. Boonstra (4), K. Laukens (2), T. Vanwolleghem (1) / [1] UZ Antwerpen, [2] U Antwerpen, [3] ZNA Stuivenberg, Borgerhout, [4] Erasmus Medical Center, Rotterdam, Netherlands (the), [5] GZA Antwerp, [6] Hospital East-Limburg

■ **12:35 - 13:15 LUNCH**

■ **13:15-14:00 Satellite Symposium GILEAD:**
The Countdown towards HEP C Elimination has started!



Chair: Marc Van Ranst (KU Leuven)
Speakers: Stefan Bratovanov & Werner De Keyzer (VZW Free Clinic Antwerp),
Astrid Marot (CHU UCL Namur), Mike Cool (AZ Damiaan Oostende),
Marie-Eve Janssen (MASS Liège), Tessa Windelinckx (GIG Coordinator),
Wim Verlinden (AZ Nikolaas, Sint-Niklaas)

14:00-15:20 - SESSION 3

**Moderators : J. Delwaide (CHU Liege),
H. Van Vlierberghe (UZ Gent)**

- **14:00 A14 Unlike HbA1c level and the amount of visceral adipose tissue, the presence and severity of NAFLD do not predict the occurrence of major adverse cardiovascular events in an obese Belgian population.**
M. Van Herck (1), C. Conrad (1), S. Kleevens (1), C. De Block (1), E. Dirinck (1),
L. Van Gaal (1), A. Verrijken (1), V. Segers (2), E. Van Craenenbroeck (2),
A. Driessen (2), P. Michiels (1), T. Steinhauser (2), T. Vanwolleghem (1),
J. Weyler (1), L. Vonghia (1), S. Francque (1) / [1] U Antwerpen, [2] UZ Antwerpen
- **14:10 A15 Do patients with NAFLD have an increased incidence of cardiovascular complications after liver transplantation?**
J. Van Herck (1), L. Verbeke (2), J. Verbeek (3), C. Verslype (3), W. Laleman (3),
H. Van Malenstein (3), D. Cassiman (3), S. Van Der Merwe (3), I. Jochmans (3),
M. Sainz Barriga (3), D. Monbaliu (3), J. Pirenne (3), F. Nevens (3) / [1] KU Leuven,
[2] AZ Sint-Maarten, Mechelen, [3] UZ Leuven
- **14:20 A16 Alcoholic liver disease and liver transplantation in patients with prior bariatric surgery.**
L. Stroobant, A. Vanlander, F. Berrevoet, X. Verhelst, Y. Van Nieuwenhove,
X. Rogiers, H. Van Vlierberghe, A. Geerts, S. Lefere / UZ Gent
- **14:30 A17 Efficacy of enteroscopy-assisted ERCP in liver transplant patients with Roux-en-Y reconstruction and suspected bile duct pathology?**
T. Moreels, P. Deprez, G. Dahlqvist, B. Delire, L. Coubeau, O. Ciccarelli,
E. Bonaccorsi Riani, P. Goffette, E. Sokal, H. Piessevaux / UCL Saint-Luc, Brussels
- **14:40-15:20 MARC HAUTEKEETE Lecture:**
Moderator: Sergio Negrin-Dastis
Prediction of mortality in cirrhotic patients before surgery.
Rosa Martín Mateos (Hospital Ramón y Cajal, Madrid, Spain)

■ **15:20-15:40 COFFEE BREAK**

2021

THE COUNTDOWN
TOWARDS **HEP C ELIMINATION**
HAS STARTED!

**MARCH
5TH
2020**

13:15 > 14:00

HILTON ANTWERP
TEUN ROOM

**JOIN US FOR A
SPICY DEBATE
AND VOTE
UPFRONT AT THE
GILEAD BOOTH**

CHAIR

Prof. MARC VAN RANST

Professor of Virology
and Epidemiology KU Leuven

FACULTY

**1 STEFAN BRATOVANOV
& WERNER DE KEYZER**

C-Buddies for VZW Free
Clinic Antwerp

2 Dr. ASTRID MAROT

Gastroenterologist
at CHU UCL Namur
(Godinne & Dinant)

3 Dr. MIKE COOL

Gastroenterologist
AZ Damiaan Oostende

4 Dr. MARIE-EVE JANSSEN

GP in addiction center
MASS Liège

5 TESSA WINDELINCKX

Coordinator of GIG
Vlaanderen & Vlaamse
Sputenruil-Hepatitis C

6 Dr. WIM VERLINDEN

Gastroenterologist
AZ Nikolaas Sint-Niklaas



PLATINUM PARTNER 2020

**BELGIAN WEEK OF
GASTROENTEROLOGY**

Moderators : P. Stärkel (UCL Brussels),
E. Bonaccorsi (UCL Brussels)

- **15:40 A18** **Myeloid IRE1a deletion alters hepatic macrophage phenotype and attenuates experimental non-alcoholic steatohepatitis-related hepatocellular carcinoma.**
S. Van Campenhout, L. Tilleman, S. Lefere, A. Vandierendonck, A. Geerts, X. Verhelst, F. Van Nieuwerburgh, H. Van Vlierberghe / UZ Gent
- **15:50 A19** **Active Non-alcoholic steatohepatitis and severe fibrosis are associated with dysfunctional adipose tissue and worsen with more severe adipose tissue insulin resistance independently of Body mass index.**
L. Vonghia (1), M. Gaggini (2), A. Verrijken (1), J. Weyler (1), F. Carli (2), B. Patricio (2), W. Kwanten (1), T. Vanwolleghem (1), E. Dirinck (1), A. Driessen (1), L. Van Gaal (1), S. Francque (1), A. Gastaldelli (2) / [1] UZ Antwerpen, [2] Institute of Clinical Physiology, Pisa, Italy
- **16:00 A20** **Muscle fat infiltration in obese patients is associated with NAFLD related fibrosis severity – results from a prospective body composition and imaging study.**
N. Lanthier, S. Hiel, M. Nachit, J. Rodriguez, J. Thissen, P. Trefois, N. Delzenne / UCL Saint-Luc, Brussels
- **16:10 A21** **The mechanisms of steatosis pathogenesis during NASH development.**
Lamotte (1), I. Leclercq (1), N. Lanthier (2) / [1] UCL, Brussels, [2] UCL Saint-Luc, Brussels
- **16:20 A22** **Neutralizing anti-CD8 antibodies effectively reduce visceral adipose tissue cytotoxic T cells and attenuate NAFLD in a high-fat high-fructose diet mouse model.**
M. Van Herck, L. Vonghia, W. Kwanten, T. Vanwolleghem, D. Ebo, P. Michielsens, J. De Man, B. De Winter, S. Francque / [1] U Antwerpen
- **16:30 A23** **Case-finding of Non-alcoholic fatty liver disease-induced liver fibrosis: prevalence and use of non-invasive scoring vs. transient elastography in primary care.**
J. Wellens (1), M. De Vos (2), L. Present (2), E. Vanderstraeten (1), S. Francque (3), L. Heyens (4), G. Robaey (4), C. Van Steenkiste (1) / [1] Maria Middelaers Medical Centre, Gent, [2] General practice Rendekens, Destelbergen, [3] UZ Antwerpen, [4] Hasselt University

- **16:40** A24 **The effects of oral bosentan treatment on the increased intrahepatic vascular resistance and disease severity of early NAFLD in rats.**
D. Van Der Graaff, W. Kwanten, J. De Man, B. De Winter, P. Michielsens, S. Francque / UZ Antwerpen
- **16:50** A25 **Impact of amino acid supplementation on sarcopenia in NASH.**
C. Pichon (1), M. Nachit (1), G. Vande Velde (2), Y. Horsmans (3), I. Leclercq (1) / [1] UCL, Brussels, [2] KU Leuven, [3] UCL Saint-Luc, Brussels
- **17:00** A26 **Assessment of liver fibrosis stage in active NASH by VCTE.**
J. Weyler (1), L. Vonghia (1), W. Verlinden (2), A. Bagdadi (1), P. Michielsens (1), T. Vanwolleghem (1), A. Driessen (1), S. Francque (1) / [1] UZ Antwerpen, [2] AZ Nikolaas, Sint-Niklaas

-
- **17:15-17:45** **Satellite Symposium ALNYLAM:**
Unravel the cause of unexplained, severe abdominal pain.

Speaker: David Cassiman (UZ Leuven)



-
- **17:45-18:00** **BASL Best Basic and Clinical Prize**
BASL General Assembly

Welcome at the Alnylam Satellite Symposium

ON THURSDAY **MARCH 5TH**
FROM 17:15 TO 17:45 IN MEETING ROOM LIJN

The right
diagnosis
is the only
way out



Unravel the cause of unexplained, severe abdominal pain

CASE REPORTS PRESENTED BY:

Prof David Cassiman, UZ Leuven • Prof Frédéric Cotton, LHUB-ULB

09:00-10:25 - SESSION 3: IBD Clinic / BeSPGHAN

Moderators : J.-F. Rahier (CHU Namur),
P. Bontemps (ULB Erasme)

- 09:00 **Invited Lecture: Current evidence for dietary treatment in Crohn's disease.**
Gigi Veereman (UZ Brussels)
- 09:25 I08 **Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohn's disease.**
N. Van Den Berghe (1), B. Verstockt (2), E. Vandeput (2), V. Ballet (2), A. Gils (1), M. Ferrante (2), S. Vermeire (2), D. Thomas (1) / [1] KU Leuven, [2] UZ Leuven
- 09:35 I09 **Safety of the sequential use of biological therapy in inflammatory bowel disease: results from a tertiary referral centre.**
A. Moens, V. Ballet, J. Sabino, S. Vermeire, M. Ferrante / UZ Leuven
- 09:45 I10 **Neoplastic lesions outside diseased area in IBD patients: A National Cohort Study.**
A. Cremer (1), P. Demetter (2), M. De Vos (3), J. Rahier (4), F. Baert (5), T. Moreels (6), E. Macken (6), E. Louis (7), S. Vermeire (8), D. Franchimont (1) / [1] ULB Erasme, Brussels, [2] Institut Jules Bordet, Brussels, [3] UZ Gent, [4] CHU UCL Namur, [5] AZ Delta, Roeselare, [6] UZ Antwerpen, [7] CHU Sart Tilman, Liège, [8] UZ Leuven
- 09:55 I11 **Prospective study of pharmacokinetics of Infliximab during induction in patients with Crohn's disease and ulcerative colitis (pacific).**
C. Liefferinckx (1), P. Bossuyt (2), D. Thomas (3), J. Rahier (4), E. Louis (5), F. Baert (6), P. Dewint (7), L. Pouillon (2), G. Lambrecht (8), S. Vermeire (9), D. Franchimont (1) / [1] ULB Erasme, Brussels, [2] Imelda Hospital, Bonheiden, [3] KU Leuven, [4] CHU-UCL-Namur site Godinne, [5] CHU Liège, [6] AZ Delta, Roeselare, [7] AZ Maria Middelaes, Gent, [8] AZ Damian, Ostende, [9] UZ Leuven
- 10:05 K01 **How switching to biosimilar infliximab led to stopping treatment in 3 pediatric Crohn patients.**
S. Vande Velde, R. De Bruyne, M. Van Winckel, V. Stephanie / UZ Gent
- 10:15 I12 **Impact of genetic burden on familial aggregation of inflammatory bowel Disease.**
H. Lee (1), L. Hannes (1), M. Vancamelbeke (1), V. Ballet (2), M. Ferrante (1), S. Vermeire (1), I. Cleynen (1) / [1] KU Leuven, [2] UZ Leuven

■ 10:25-10:55 **Satellite Symposium BIOGEN:**
BIOSIMILARS: A Fuel to Innovation.

Speaker: Pieter Dewint (AZ Maria Middelaes, Gent /
UZ Antwerpen)



■ 10:55-11:10 **COFFEE BREAK**

11:10-12:30 - SESSION 4

Moderators : P. Dewint (AZ Maria Middelaes, Gent / UZ Antwerpen),
P. Bossuyt (IMELDA, Bonheiden)

- 11:10 **Invited Lecture: How can telemedicine and patient empowerment improve IBD care in 2020?**
Marieke Pierik (University of Maastricht, Netherlands)
- 11:35 I13 **Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation.**
N. Van Den Berghe, B. Verstockt, A. Gils, M. Ferrante, S. Vermeire, D. Thomas /
UZ Leuven
- 11:45 I14 **Safety and efficacy of combining biological therapies together or with Small molecules in patients with Inflammatory Bowel Disease: a retrospective multicenter national observational case series study.**
L. Goessens (1), J. Colombel (2), A. Outtier (3), M. Ferrante (3), M. Truyens (4),
T. Lobaton (4), F. Baert (5), P. Bossuyt (6), A. Cremer (7), E. Macken (8),
B. Strubbe (9), J. Rahier (1) / [1] CHU UCL Namur, Site de Godinne, Yvoir,
[2] Mount Sinai School of Medicine, New York, USA, [3] UZ Leuven, [4] UZ Gent,
[5] AZ Delta, Roeselare, [6] Imelda Hospital, Bonheiden, [7] ULB Erasme, Bruxelles,
[8] UZ Antwerpen, [9] AZ Sint-Lucas, Gent



BIOSIMILARS : A FUEL TO INNOVATION

BELGIAN WEEK OF GASTROENTEROLOGY, XXXIInd Edition
Hilton Hotel, Antwerp
Satellite Symposium
5 March 2020, 10H30 – 11H00



- 10H30– 10H50 : First results of the Belgian Safe-Orbi study.
Dr. Pieter Dewint
Gastroenterologist
AZ Maria Middelaers, Ghent
Belgium
- 10H50– 11H00 : Q&A, Discussion and final conclusions



BIOSIMILARS : A FUEL TO INNOVATION

BELGIAN WEEK OF GASTROENTEROLOGY, HOTEL HILTON, ANTWERP, 5 March 2020, 10H30-11H00

BIOGEN-40258 January 2020

■ 11:55 I15

Tofacitinib induces clinical and endoscopic remission in biologic refractory Ulcerative Colitis patients: A real-world Belgian cohort study.

A. Cremer (1), T. Lobaton (2), S. Vieujan (3), P. Bossuyt (4), J. Rahier (5), F. Baert (6), O. Dewit (7), E. Macken (8), M. Somers (8), A. Vijverman (9), P. Van Hootegem (10), F. Mana (11), B. Willandt (12), P. Caenepeel (13), E. Humblet (13), F. D'heygere (14), A. Verreth (15), A. El Nawar (16), J. Coenegrachts (17), S. Dewit (18), S. De Coninck (19), N. Schoofs (20), S. Delen (21), J. Dutre (22), C. Thienpont (23), S. Vanden Branden (24), D. Staessen (25), D. Franchimont (1) / [1] ULB Erasme, Brussels, [2] UZ Gent, [3] CHU Sart Tilman, Liège, [4] Imelda Hospital, Bonheiden, [5] CHU UCL Namur, Yvoir, [6] AZ Delta, Roeselare, [7] UCL Saint-Luc, Brussels, [8] UZ Antwerpen, [9] CHR Citadelle, Liège, [10] AZ Sint-Lucas, Gent, [11] Clinique Saint-Jean, Brussels, [12] AZ Sint-Jan BruggeOostende, [13] ZOL, Genk, [14] AZ Groeninge, Kortrijk, [15] AZ Sint-Jozef, Malle, [16] Centre Hospitalier Mouscron, [17] Jessa Ziekenhuis, Hasselt, [18] Mariaziekenhuis Noord-Limburg, Overpelt, [19] Sint Andries Ziekenhuis Tielit, [20] Sint-Trudo Ziekenhuis, Sint-Truiden, [21] ZH Maas en Kempen, [22] ZNA Jan Palfijn, Merksem, [23] ZNA Antwerpen, [24] OnzeLieveVrouwziekenhuis, Aalst, [25] GZA Sint-Vincentius Ziekenhuis, Antwerpen

■ 12:05

Invited Lecture: How to do a tight monitoring in Crohn's disease: role of small bowel capsule endoscopy, entero-MRI and other morphologic explorations.

Arnaud Bourreille (University of Nantes, France)

■ 12:30-13:15

Satellite Symposium JANSSEN:
Will Treat-to-Target with early endoscopic assessment lead to better outcomes?

Speakers: Mark Löwenberg, Floris de Voogd
(AMC Amsterdam, The Netherlands)



■ LUNCH

Janssen-Sponsored Satellite Symposium at the Belgian Week of Gastroenterology (BWGE) – 32nd edition, Antwerp, Belgium

Will Treat-to-Target with early endoscopic assessment lead to better outcomes?

(Preliminary) answers from the STARDUST¹ trial of ustekinumab in Crohn's disease*

Thursday March 5 from 12.30 - 13.15

Speakers

Dr. Mark Löwenberg & Dr. Floris de Voogd

Gastroenterology Unit, Academisch Medisch Centrum (AMC) in Amsterdam, the Netherlands

Program

- 12.30 - 12.50: STARDUST trial: preliminary results and how to translate these into your daily clinical practice
- 12.50 - 13.10: STARDUST substudy: ultra-sounds, a viable alternative to ileocolonoscopy
- 13.10 - 13.15: Q&A session / Conclusion and closing

Venue

Hilton Hotel Antwerp - Conference Center, Room "Lijn"

1. Danese S, et al. DOP13 presented at European Crohn's and Colitis Organisation (ECCO) 15th congress, 12–15 February 2020, Vienna, Austria
For additional information consult the Stelara SmPC.

* STELARA is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF α antagonist or have medical contraindications to such therapies.

13:00 – 14:00 GUIDED E-POSTER TOUR

Moderators : R. Bisschops (UZ Leuven),
P. Eisendrath (ULB Saint-Pierre),
A. Lemmers (ULB Erasme)

- G11 **A multinational retrospective, cohort study of patients with Buried Bumper Syndrome treated endoscopically with a novel dedicated device.**
D. Costa (1), P. Hindryckx (2), E. Despott (1), A. Murino (1) /
[1] The Royal Free Hospital and University College London (UCL) Institute for Liver and Digestive Health, UK, [2] UZ Gent
- G12 **Automated polyp size estimation with deep learning reduces interobserver variability.**
J. Suykens, T. Eelbode, J. Daenen, P. Suetens, F. Maes, R. Bisschops /
UZ Leuven
- G13 **EUS-directed transgastric intervention (EDGE) in patients with surgically altered anatomy: monocentric experience.**
L. Monino, T. Moreels, H. Piessevaux, Ph. Deprez / UCL Saint-Luc, Brussels
- G14 **The Real Life Diagnostic Accuracy of Regular Arrangement of Collecting Venules in Detecting H.pylori-negative Patients.**
C. De Bie, E. Dubois, M. Bronswijk, R. Bielen, R. Bisschops / UZ Leuven
- G15 **What matters for your patient during gastrointestinal endoscopy: an exploratory research on patient experience and satisfaction.**
M. Surmont (1), Z. Del Rio (2), L. Skenazi (2), C. Hellemans (2), P. Eisendrath (1) /
[1] CHU Saint-Pierre, Brussels, [2] ULB, Brussels
- G16 **ESD for oesophageal squamous cell carcinoma: a European tertiary centre Prospectively collected experience.**
M. Figueiredo Ferreira, A. Bucalau, V. Huberty, L. Verset, C. Maris,
J. Van Laethem, I. El Nakadi, J. Devière, A. Lemmers / ULB Erasme, Bruxelles
- G17 **A new 12-French plastic stent may be an alternative in unresectable distal malignant biliary obstruction.**
Ph. Deprez, T. Moreels, T. Aouattah, H. Piessevaux,
E. Pérez-Cuadrado-Robles / UCL Saint-Luc, Brussels
- G18 **Obstructive complications related to the use of self-expandable metallic stent for the treatment of distal biliary stricture.**
W. Soub Defeu, J. Devière, A. Lemmers / C.U.B. ULB Erasme, Brussels

- G19 **We cannot teach our endoscopists to accurately size polyps: a follow-up on the Oostende polyp sizing study.**
S. Van Langendonck (1), A. Billiet (2), K. Hertveldt (3), M. Cool (3), G. Lambrecht (3), G. Deboever (3) / [1] UZ Antwerpen, [2] UZ Leuven, [3] AZ Damiaan
- G20 **Risk Stratification of patients in ER presenting with acute upper gastrointestinal bleed using extended Glasgow Blatchford score.**
D. Krishnan (1), G. Panchakapesan (2), S. Shanmughanathan (2) / [1] Sree Ramachandra Medical College, India
- G21 **Same day propofol sedation does not impair the completion rate of capsule endoscopy.**
O. De Ronde, T. De Ronde, F. Wuestenberghs / CHU UCL Namur, Site de Godinne, Yvoir
- G22 **Partially covered metallic stent for treatment of gastric leak after sleeve gastrectomy: a retrospective monocentric experience of 760 consecutives surgical procedures.**
B. Vos, J. Rigaux, S. Evrard / Chirec, Braine-l'Alleud
- G23 **Radiofrequency ablation of Barrett esophagus: post reimbursement experience of a tertiary Belgian hospital.**
S. Ouazzani (1), A. Lemmers (1), N. D'haene (1), L. Verset (2), J. Deviere (1), P. Eisendrath (3) / [1] ULB Erasme, Brussels, [2] ULB Institut Jules Bordet, Brussels, [3] ULB Saint-Pierre, Brussels

14:00-14:48 - SESSION 1: Diagnostic innovations in endoscopy

Moderators : P. Dewint (AZ Maria Middelaers, Gent / UZ Antwerpen),
M. Figueiredo (ULB Erasme),
S. Van Langendonck (UZ Antwerpen)

■ **14:00 G01** **Wide area transepithelial sample esophageal biopsy combined with computer assisted 3-dimensional tissue analysis (WATS3D) for the detection of high grade dysplasia and adenocarcinoma in Barrett: European multi-center, prospective, randomized, Tandem study.**

R. Bisschops (1), R. Haidry (2), H. Messmann (3), K. Ragunath (4), P. Bhandari (5), A. Repici (6), M. Munoz-Navas (7), S. Seewald (8), A. Lemmers (9), A. Castells (10), O. Pech (11), E. Schoon (12), R. Kariv (13), H. Neuhaus (14), B. Weusten (15), P. Siersema (16), L. Correale (17), F. Fromowitz (18), G. De Hertogh (1), J. Bergman (19), C. Hassan (17) / [1] UZ Leuven, Belgium, [2] University College London Hospitals, UK, [3] Clinic Augsburg III, Germany, [4] Nottingham University Hospital, UK, [5] Queen Alexandra Hospital Solent Centre for Digestive Diseases, Portsmouth, UK, [6] Humanitas Research Hospital & Humanitas University, Milan, Italy, [7] Universidad de Navarra, Spain, [8] Clinic Hirslanden GastroZentrumHirslanden, Zurich, Switzerland, [9] ULB Erasme, Brussels, [10] Hospital Clinic of Barcelona, Spain, [11] Krankenhaus Barmherzige Brüder Regensburg, Germany, [12] Catherina Ziekenhuis Eindhoven, The Netherlands, [13] Tel Aviv Sourasky Medical Center, Israel, [14] University of Düsseldorf Evangelisches Krankenhaus, Germany, [15] Antonius Ziekenhuis, Nieuwegein, The Netherlands, [16] Radboud UMC, Nijmegen, The Netherlands, [17] Nuovo Regina Margherita Hospital, Rome, Italy, [18] Cdx Diagnostics, Suffern, USA, [19] Amsterdam UMC, The Netherlands

■ **14:12 G02** **A prospective, multi-center validation study for automated polyp detection as a second observer.**

T. Eelbode (1), C. Hassan (2), H. Neumann (3), I. Demedts (1), P. Sinonquel (1), P. Roelandt (1), C. Camps (1), E. Coron (4), P. Bhandari (5), O. Pech (6), H. Willekens (1), F. Maes (1), R. Bisschops (1) / [1] UZ Leuven, Belgium, [2] Nuovo Regina Margherita Hospital, Rome, Italy, [3] University Medical Center Mainz, Germany, [4] CHU Nantes, France, [5] Portsmouth Hospital, UK, [6] Krankenhaus Barmherzige Brüder Regensburg, Germany

■ **14:24 G03** **The incremental benefit of dye-based chromoendoscopy as compared to high-definition white light and virtual chromoendoscopy for lesion assessment and prediction of SMI.**

M. Sidhu (1), D. Tate (2), M. Bourke (1) / [1] Westmead Hospital, Australia, [2] UZ Gent

■ **14:36 G04** **Mucosal capillary pattern recognition based on automated image analysis during endoscopy accurately detects histological remission in ulcerative colitis.**

P. Bossuyt (1), G. De Hertogh (2), T. Eelbode (2), S. Vermeire (2), R. Bisschops (2) / [1] Imelda Hospital, Bonheiden, [2] UZ Leuven

14:48-16:12 - SESSION 2: Quality in Endoscopy

Moderators : T. Moreels (UCL Saint-Luc),
M. Bronswijk (UZ Leuven),
H. Degroote (UZ Gent)

- 14:48 G05 **Continuous ADR50 monitoring with individual feedback in lower gastrointestinal endoscopy, a quality improvement initiative in a Brussels public hospital.**

G. Rasschaert, L. Duez, C. Salem, C. Musala, M. Nkuize, P. Eisendrath /
[1] CHU Saint-Pierre, Brussels

- 15:00 **Invited Lecture: Management of common bile duct stones.**

Peter Meier (Hannover, Germany)

■ 15:30 - 16:00 COFFEE BREAK

- 16:00 G06 **Thermal ablation of the mucosal defect margin after endoscopic mucosal resection significantly reduces adenoma recurrence – A prospective, international, multi-centre trial.**

M. Sidhu (1), N. Shahidi (1), L. Hourigan (2), S. Raftopoulos (3), A. Moss (4),
S. Heitman (5), E. Lee (1), N. Burgess (1), S. Williams (1), D. Tate (6), M. Bourke (1)
/ [1] Westmead Hospital, Australia, [2] Greenslopes Private Hospital, Australia,
[3] Sir Charles Gairdner, Australia, [4] Western Hospital, Australia, [5] University of
Calgary, Canada, [6] UZ Gent

16:12-18:15 - SESSION 3: Outcomes in Therapeutic Endoscopy

- 16:12 G07 **EUS-guided intrahepatic access for retrograde, antegrade or transgastric biliary drainage: indications, efficacy and safety from an 8-year tertiary centre experience.**

M. Bronswijk, G. Vanella, H. Van Malenstein, W. Laleman, S. Van Der Merwe (1) /
[1] UZ Leuven

- 16:24 G08 **Electrocautery-enhanced lumen-apposing metal stents for approved and non-approved indications: a 2-year single-centre experience.**

P. Hindryckx, H. Degroote / UZ Gent

- 16:36 G09 **Covert carcinoma among rectal ESD specimen is high: a European tertiary center prospectively collected experience.**

M. Figueiredo Ferreira, A. Bucalau, V. Huberty, L. Verset, C. Maris,
J. Van Laethem, I. El Nakadi, A. Lemmers / ULB Erasme, Bruxelles

- 16:36 G10 **Superficial adenocarcinoma of the esophagogastric junction (AEGJ): outcomes of ESD in a Western cohort.**
M. Lefebvre, T. Moreels, H. Piessevaux, C. Snauwaert, H. Dano, Ph. Deprez /
UCL Saint-Luc, Brussels
- 16:50 **Invited Lecture: Endoscopic management of chronic pancreatitis.**
A. Tringali (Roma, Italy)
- 17:20 **BSGIE Award Ceremony**
 - Best Oral Presentation
 - Best Abstract
- 17:30-18:15 **Belgian group of young GI Endoscopists (BygGIE) Meeting**

**FOR YOUR HCV PATIENTS,
PANGENOTYPIC - PANFIBROTIC.**

EPCLUSA

SIMPLE AND CONVENIENT

ONE PILL.
ONCE A DAY.
ONE DURATION.

**FREE FROM FOOD RESTRICTIONS.
RBV* AND PI FREE.
FEW DRUG-DRUG INTERACTIONS.
FEW ADVERSE EVENTS.**

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SPC for how to report adverse reactions. **NAME OF THE MEDICINAL PRODUCT** Epclusa 400 mg/100 mg film coated tablets. **QUALITATIVE AND QUANTITATIVE COMPOSITION** Each film coated tablet contains 400 mg sofosbuvir and 100 mg velpatasvir. For the full list of excipients, see section 6.1 of the SPC. **PHARMACEUTICAL FORM** Film coated tablet. Pink, diamond shaped, film coated tablet of dimensions 20 mm x 10 mm, debossed on one side with "GSI" and "7916" on the other side. **THERAPEUTIC INDICATIONS** Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults. **POSLOGY AND METHOD OF ADMINISTRATION** Epclusa treatment should be initiated and monitored by a physician experienced in the management of patients with HCV infection. **Posology** The recommended dose of Epclusa is one tablet, taken orally, once daily with or without food. **Table 1: Recommended treatment and duration for all HCV genotypes**

Patient population*	Treatment and duration
Patients without cirrhosis and patients with compensated cirrhosis	Epclusa for 12 weeks
Patients with decompensated cirrhosis	Epclusa + ribavirin for 12 weeks

* Includes patients coinfecting with human immunodeficiency virus (HIV) and patients with recurrent HCV post-liver transplant.

When used in combination with ribavirin, refer also to the Summary of Product Characteristics of the medicinal product containing ribavirin. The following dosing is recommended where ribavirin is divided in two daily doses and given with food: **Table 2: Guidance for ribavirin dosing when administered with Epclusa to patients with decompensated cirrhosis**

Patient	Ribavirin Dose
Child/Pugh/Turcotte (CPT) Class B cirrhosis pre-transplant	1,000 mg per day for patients < 75 kg and 1,200 mg for those weighing ≥ 75 kg
CPT Class C cirrhosis pre-transplant	Starting dose of 600 mg, which can be titrated up to a maximum of 1,000/1,200 mg (1,000 mg for patients weighing < 75 kg and 1,200 mg for patients weighing ≥ 75 kg) if well tolerated. If the starting dose is not well tolerated, the dose should be reduced as clinically indicated based on haemoglobin levels
CPT Class B or C post-transplant	

If ribavirin is used in genotype 3 infected patients with compensated cirrhosis (pre- or post-transplant) the recommended dose of ribavirin is 1,000/1,200 mg (1,000 mg for patients weighing < 75 kg and 1,200 mg for patients weighing ≥ 75 kg). For ribavirin dose modifications, refer to the Summary of Product Characteristics of the medicinal product containing ribavirin. Patients should be instructed that if vomiting occurs within 3 hours of dosing an additional tablet of Epclusa should be taken. If vomiting occurs more than 3 hours after dosing, no further dose of Epclusa is needed. If a dose of Epclusa is missed and it is within 18 hours of the normal time, patients should be instructed to take the tablet as soon as possible and then patients should take the next dose at the usual time. If it is after 18 hours then patients should be instructed to wait and take the next dose of Epclusa at the usual time. Patients should be instructed not to take a double dose of Epclusa. Patients who have previously failed therapy with an NS5A-containing regimen Epclusa + ribavirin for 24 weeks may be considered. Elderly No dose adjustment is warranted for elderly patients. Renal impairment No dose adjustment of Epclusa is required for patients with mild or moderate renal impairment. Safety data are limited in patients with severe renal impairment (estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m²) and end stage renal disease (ESRD) requiring haemodialysis. Epclusa can be used in these patients with no dose adjustment when no other relevant treatment options are available. Hepatic Impairment No dose adjustment of Epclusa is required for patients with mild, moderate, or severe hepatic impairment (CPT Class A, B, or C). Safety and efficacy of Epclusa have been assessed in patients with CPT Class B

cirrhosis, but not in patients with CPT Class C cirrhosis. **Paediatric population** The safety and efficacy of Epclusa in children and adolescents aged less than 18 years have not yet been established. No data are available. **Method of administration** For oral use. Patients should be instructed to swallow the tablet whole with or without food. Due to the bitter taste, it is recommended that the film coated tablet is not chewed or crushed. **CONTRAINDICATIONS** Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 of the SPC. **Use with strong P gp and strong CYP inducers** Medicinal products that are strong P glycoprotein (P gp) and/or strong cytochrome P450 (CYP) inducers (carbamazepine, phenobarbital, phenytoin, rifampicin, rifabutin and St. John's wort). Co administration will significantly decrease sofosbuvir or velpatasvir plasma concentrations and could result in loss of efficacy of Epclusa. **UNDESIRABLE EFFECTS** Summary of the safety profile The safety assessment of Epclusa was based on pooled Phase 3 clinical study data from patients with genotype 1, 2, 3, 4, 5 or 6 HCV infection (with or without compensated cirrhosis) including 1,035 patients who received Epclusa for 12 weeks. The proportion of patients who permanently discontinued treatment due to adverse events was 0.2% and the proportion of patients who experienced any severe adverse events was 3.2% for patients receiving Epclusa for 12 weeks. In clinical studies, headache, fatigue and nausea were the most common (incidence ≥ 10%) treatment emergent adverse events reported in patients treated with 12 weeks of Epclusa. These and other adverse events were reported at a similar frequency in placebo treated patients compared with Epclusa treated patients. **Patients with decompensated cirrhosis** The safety profile of Epclusa has been evaluated in one open label study in which patients with CPT Class B cirrhosis received Epclusa for 12 weeks (n = 90), Epclusa + RBV for 12 weeks (n = 87) or Epclusa for 24 weeks (n = 90). The adverse events observed were consistent with expected clinical sequelae of decompensated liver disease, or the known toxicity profile of ribavirin for patients receiving Epclusa in combination with ribavirin. Among the 87 patients who were treated with Epclusa + RBV for 12 weeks, decreases in haemoglobin to less than 10 g/dL and 8.5 g/dL during treatment were experienced by 23% and 7% patients, respectively. Ribavirin was discontinued in 15% of patients treated with Epclusa + RBV for 12 weeks due to adverse events. **Patients with renal impairment** The safety of Epclusa has been evaluated in a 12-week non-controlled study including 59 subjects with ESRD requiring dialysis (Study 4062). In this setting, exposure of sofosbuvir metabolite GS-331007 was 20-fold increased, exceeding levels where adverse reactions have been observed in preclinical trials. In this limited clinical safety data set, the rate of adverse events and deaths was not clearly elevated from what is expected in ESRD patients. **Description of selected adverse reactions** Cardiac arrhythmias Cases of severe bradycardia and heart block have been observed when sofosbuvir-containing regimens are used in combination with amiodarone and/or other medicinal products that lower heart rate. **Skin disorders** Frequency not known: Stevens-Johnson syndrome Reporting of suspected adverse reactions **Reporting suspected adverse reactions** after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. **Belgium** Federaal agentschap voor geneesmiddelen en gezondheidsproducten Afdeling Vigilantie EURASTATION II Victor Hortaplein, 40/40 B-1060 Brussel Postbus 97 B-1000 Brussel Madou Website: www.fagb.be; e-mail: adversedrugreactions@fagb-famfs.be **Luxembourg** Centre Régional de Pharmacovigilance de Nancy Bâtiment de Biologie Moléculaire et de Biopathologie (BBB) CHRU de Nancy – Hôpitaux de Brabois Rue du Manoir 54 511 VANDOEUVRE LES NANCY CEDEX Tél : (+33) 3 83 65 60 85 / 87 Fax : (+33) 3 83 65 61 33 E-mail : crpv@chru-nancy.fr or Direction de la Santé Division de la Pharmacie et des Médicaments Allée Marconi – Villa Louvigny L-2120 Luxembourg Tél : (+352) 2478 5592 Fax : (+352) 2479 5615 E-mail : pharmacovigilance@ms.etat.lu Link pour le formulaire : <http://www.sante.public.lu/fr/politique-sante/ministere-sante/direction-sante/div-pharmacie-medicaments/index.html> **MARKETING AUTHORISATION HOLDER** Gilead Sciences Ireland UC Carrigrohilly County Cork, T45 DP77 Ireland **MARKETING AUTHORISATION NUMBER(S)** EU/1/16/116/001 **DATE OF REVISION OF THE TEXT** 10/2019 **MODE OF DELIVERY** Prescription only **PRICE** € 8000 (ex factory) € 8745.35 (public price) Detailed information on the medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu>



EPCE/BE/18-10/1534(2) - November 2019



WEDNESDAY 04/03

THURSDAY 05/03

FRIDAY 06/03

3^{dr} floor

BELLE EPOQUE	LIJN	TEUN
■ 10.10-10.40 Coffee break ■ 12.20-14.00 LUNCH «EXHIBITION AREA» ■ 15.25-16.00 Coffee break «EXHIBITION AREA» ■ 17.00-18.00 Welcome Drink	■ 08.30-10.10 Post Graduate Course ■ 10.40-12.20 Post Graduate Course ■ 13.45-15.25 Post Graduate Course ■ 16.00-17.15 Post Graduate Course	
■ 10.00-10.45 Coffee break «EXHIBITION AREA» ■ 12.00-14.00 LUNCH «EXHIBITION AREA» ■ 12.15-13.00 SHORT ORAL PRESENTATIONS OF THE BEST E-POSTERS: BASIC SCIENCE ■ 15.30-16.00 Coffee break «EXHIBITION AREA»	■ 08.30-10.00 BIRD Clinical / BeSPGHAN ■ 10.25-10.55 Satellite Symposium BIOGEN ■ 11.10-12.30 BIRD Clinical / BeSPGHAN ■ 12.30-13.15 Satellite Symposium JANSSEN-CILAG ■ 13.00-14.00 BSGIE e-Poster Session ■ 14.00-15.30 BSGIE ■ 16.00-17.30 BSGIE ■ 17.30 - 18.15 BygGIE Meeting	■ 08.00-08.30 Breakfast Symposium EISAI / MSD ■ 08.20-09.30 BASL ■ 09.30-10.00 Brohee Lecture ■ 10.00-10.30 Satellite Symposium BAYER ■ 10.45-12.35 BASL ■ 13.15-14.00 Satellite Symposium GLEAD ■ 14.00-15.20 BASL ■ 15.40-17.15 BASL ■ 17.15-17.45 Satellite Symposium ALNYLAM ■ 17.45-18.00 BASL Prizes & General Assembly
■ 10.30-11.00 Coffee break «EXHIBITION AREA» ■ 12.00-14.00 LUNCH «EXHIBITION AREA» ■ 12.15-13.00 BEST E-POSTERS CLINICAL FOR ORAL PRESENTATION ■ 13.30-14.00 BIOCODEX GRANT ■ 15.30-16.00 Coffee break «EXHIBITION AREA»	■ 09.00-10.00 Working Group of Digestive Pathology ■ 10.30-12.30 Working Group of Digestive Pathology ■ 12.30-13.00 GBS-VBS General Assembly ■ 13.30-15.00 Working Group of Digestive Pathology ■ 15.30-16.30 Working Group of Digestive Pathology	■ 08.30-09.00 Breakfast Symposium ELI LILLY ■ 09.00-10.30 BGDO ■ 11.00-12.15 BGDO ■ 14.00-15.30 Belgian Pancreatic Club ■ 16.00-17.10 Belgian Pancreatic Club

2 nd floor			
SANCY	TIFFANY/SHAH	FLORENTINE	HOPE
14.00-15.30 Young BASL 16.00-17.40 Young BASL 17.45-18.30 GIREM Meeting	14.00-15.30 BIRD Basic 15.30-16.00 Satellite Symposium TAKEDA 16.00-17.00 BIRD Basic 17.00-17.45 Satellite Symposium PFIZER 17.45-18.30 General Assembly IBD	17.00-19.00 ULTRA SOUND Course	WARDROBE 
09.00-10.15 Case Reports Gastroenterology 10.45-12.00 Case Reports Gastroenterology 13.00-14.00 BeSPGHAN General Assembly 14.00-15.00 BeSPGHAN 15.00-17.00 BeSPGHAN 18.00-19.00 ACTA General Assembly	09.00-10.30 GIREM 11.00-12.30 GIREM 13.30-15.30 GIREM 16.00-17.30 GIREM 17.30-18.30 Brohée Fund General Assembly		WARDROBE 
09.00-10.15 Case Reports Hepatology 10.45-12.00 Case Reports Hepatology	09.00-10.30 BSGIE Live Transmission Session 11.00-12.00 BSGIE Live Transmission Session 14.00-16.00 Proctology		WARDROBE 

09:00-10:30 - SESSION 1

Moderators : W. Boesmans (Hasselt University),
R. Farré (KULeuven)

- 09:00 **Invited Lecture: Characterizing the development of coordinated activity in the human fetal gut neuromusculature.**
Conor McCann (UCL Great Ormond Street Institute of Child Health, Stem Cells and Regenerative Medicine, London, UK)
- 09:45 B01 **Human and bacterial-derived amyloids trigger a distinct transcriptional response in primary myenteric networks.**
N. De Loose (1), P. Verstraelen (1), G. Garcia-Diaz Barriga (1), S. Van Remoortel (1), E. Bartholomeus (1), A. Braun (2), M. Gries (2), K. Schäfer (2), W. De Vos (1), J. Timmermans (1) / [1] U Antwerpen, [2] University of Applied Sciences Kaiserslautern, Zweibrücken, Germany
- 10:00 B02 **Sex-difference in the gastrointestinal phenotype depends on the susceptibility for co-morbid disorders such as anxiety.**
S. Wellens, A. Accarie, J. Toth, L. Wauters, R. Farré, J. Tack, T. Vanuytsel / KU Leuven
- 10:15 B03 **Examining the processing of luminal information by the Enteric Nervous System using Ca²⁺ imaging.**
C. Fung (1), M. Hao (2), J. Tack (1), W. Boesmans (3), P. Vanden Berghe (1) / [1] KU Leuven, [2] University of Melbourne, Parkville, Australia, [3] U Hasselt

■ 10:30-11:00 COFFEE BREAK

11:00-12:30 - SESSION 2

Moderators : A. Smet (UAntwerpen), K. Liszt (KULeuven)

- 11:00 **Invited Lecture: The contribution of sodium channels to sensory Perception in the gut.**
Frank Bosmans (UGent)
- 11:45 B04 **Beneficial effects of the locally administered TRPV4-antagonist HC-067047 in a post-inflammatory rat model for visceral hypersensitivity.**
N. Hanning (1), H. Ceuleers (1), S. Van Remoortel (1), H. De Schepper (2), A. Smet (1), J. Timmermans (1), J. De Man (1), B. De Winter (1) / [1] U Antwerpen, [2] UZ Antwerpen
- 12:00 B05 **Duodenal bile salts and mucosal changes are linked with gastric emptying and symptoms in functional dyspepsia patients.**
L. Wauters, M. Ceulemans, M. Lambaerts, A. Accarie, J. Toth, R. Mols, R. Farré, P. Augustijns, J. Tack, T. Vanuytsel / KU Leuven

- 12:15 B06 **Inhibition of adhesiogenesis with protease inhibitors Nafamostat Mesylate, UAMC-00050, and Enoxaparin in a murine model for sepsis and peritonitis.**

P. Plaeke (1), J. De Man (1), A. Smet (1), I. De Meester (1), K. Augustyns (1), P. Jorens (2), G. Hubens (2), B. De Winter (1) / [1] U Antwerpen, [2] U Antwerpen / UZ Antwerpen

■ 12:30-13:30 LUNCH

13:30-15:30 - SESSION 3

Moderators : L. Devisscher (UGent), G. Matteoli (KULeuven)

- 13:30 **Invited Lecture: The gut-liver axis in health and disease – prospects of understanding and targeting macrophages.**
Alexander Wree (Berlin, Germany)
- 14:15 B07 **Crosstalk between monocyte-derived macrophages and enteric glial cell is essential for tissue repair and recovery of gastrointestinal transit after intestinal inflammation.**
S. Ibiza (1), M. Stakenborg (1), S. Abdu Rahiman (1), V. De Simone (1), B. Ke (1), Q. Wu (1), D. Pirottin (2), T. Marichal (2), G. Matteoli (1) / [1] KU Leuven, [2] ULg, Liège
- 14:30 B08 **Role of bitter taste receptors on innate immunity in jejunal crypts from lean and obese subjects.**
K. Liszt (1), Q. Wang (1), A. Segers (1), L. Ceulemans (2), B. Van Der Schueren (2), M. Lannoo (2), D. Inge (1) / [1] KU Leuven, [2] UZ Leuven
- 14:45 B09 **Anti-inflammatory effects on duodenal eosinophilia rather than acid-suppressive effects explain therapeutic efficacy of proton pump Inhibitors in functional dyspepsia patients.**
M. Ceulemans, L. Wauters, D. Frings, A. Accarie, R. Farre, G. De Hertogh, J. Tack, T. Vanuytsel / KU Leuven
- 15:00 B10 **Innate immune cell populations characterise the disrupted gut-liver axis In Experimental PSC-UC.**
K. De Muynck, B. Vanderborght, S. Van Campenhout, L. Devisscher / UGent
- 15:15 B11 **Economic burden in primary care irritable bowel syndrome patients with different stool pattern subtypes.**
K. Van Den Houde (1), C. Tack (1), J. Biesiekierski (2), L. Besard (3), J. Schol (1), E. Colomier (1), F. Carbone (1), J. Tack (1) / [1] KU Leuven, [2] La Trobe University, Victoria, Australia, [3] UZ Leuven

■ 15:30-16:00 COFFEE BREAK

16:00-17:20 - SESSION 4

Moderators : W. De Vos (UAntwerpen), T. Vanuytsel (KULeuven)

- 16:00 B12 **Exploring the molecular signalling pathways of MUC1 and MUC13 in intestinal epithelial cells during inflammation in vitro: important mediators of intestinal barrier integrity?**
T. Breugelmans, B. Cuypers, J. De Man, K. Laukens, B. De Winter, A. Smet / U Antwerpen
- 16:15 B13 **Postinfectious onset in functional dyspepsia is a risk factor for weight loss.**
J. Schol, F. Carbone, K. Van Den Houte, E. Colomier, J. Tack / KU Leuven
- 16:30 B14 **Volatile organic compound profiling of breath samples as a biomarker to discriminate between patients with irritable bowel syndrome and healthy controls: a feasibility study.**
K. Van Malderen (1), E. Janssens (1), J. De Man (1), B. De Winter (1), H. De Schepper (2), K. Lamote (1) / [1] U Antwerpen, [2] UZ Antwerpen
- 16:45 B15 **Predictors of treatment response to the traditional and the low FODMAP diet for patients with irritable bowel syndrome.**
E. Colomier (1), L. Van Oudenhove (1), J. Tack (1), L. Böhn (2), S. Bennet (2), S. Störsrud (2), L. Öhman (2), H. Törnblom (2), M. Simrén (2) / [1] KU Leuven, [2] University of Gothenburg, Sweden
- 17:00 B16 **Somatization, anxiety, depression and fear of pain levels are not significantly different across the gastroesophageal reflux disease spectrum.**
A. Geeraerts, L. Van Oudenhove, H. Geysen, T. Vanuytsel, J. Tack, A. Pauwels / KU Leuven
- 17:20 **End of the Session**



**COMMITMENT THAT GOES BEYOND
MEDICINES**

FOR THE
PEACE
WITHIN

We're working on a future where
immune-mediated disease is a
thing of the past

Janssen-Cilag NV

janssen  Immunology

PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*

Interactive Case Report

Session: Gastroenterology

ROOM:
SANCY

09:00-10:15 - SESSION 1

Moderators : D. De Looze (UZ Gent), C. Van Kemseke (ULG Liège)

- **09:00** C01 **A curious case of collagenous colitis.**
S. De Meulder (1), F. Van De Mierop (2) / [1] UZ Leuven, [2] Sint Augustinus Ziekenhuis GZA, Antwerp
- **09:15** C02 **Intestinal spirochetosis: Think about it to diagnose it.**
F. Hamoir (1), N. De Suray (1), J. Dargent (2), P. Warzee (1) / [1] GHDC, Charleroi, [2] IPG, Charleroi
- **09:30** C03 **An ileal GIST as a rare cause of overt lower gastro-intestinal bleeding in a 25-year old woman: a case report.**
E. Van Mieghem, S. Van Outryve, J. Wauters, P. Steger / GZA Sint-Vincentius Ziekenhuis, Antwerpen
- **09:45** C04 **Pseudo-achalasia secondary to oesophageal deviation resulting from mediastinal shift and right atrial enlargement after left lower lobectomy.**
M. Surmont, M. Aerts, R. Kunda, S. Kindt / UZ Brussel
- **10:00** C05 **A PET-positive nodule after chemotherapy.**
A. Van Oosterwyck (1), M. Cool (1), G. Deboever (1), L. Depypere (2), G. Van Parys (3), G. Lambrecht (1) / [1] AZ Damiaan, Oostende, [2] UZ Leuven, [3] AZ Damiaan, Oostende

■ **10:15-10:45** **COFFEE BREAK**

Interactive Case Report

Session: Gastroenterology

ROOM:
SANCY

10:45-12:00 - SESSION 2

Moderators : D. De Looze (UZ Gent), C. Van Kemseke (ULG Liège)

- **10:45** C06 **Neoadjuvant immunotherapy for a MSI-H locally advanced rectal cancer patient: should we define new standard of care for these patients?**
L. Mans, M. Pezzullo, A. Bucalau, N. D'haene, J. Van De Stadt, J.-L. Van Laethem / ULB Erasme Brussels
- **11:00** C07 **Spontaneous Pneumobilia.**
L. Janssens, D. Penrice, J. Brant, M. Halland / Mayo Clinic, Rochester, USA
- **11:15** C08 **Not probiotic-related *Saccharomyces cerevisiae* fungemia in an intensive care patient, a case report.**
M. Moretti (1), E. Maillart (2), B. Mahadeb (2), P. Clevenbergh (2) / [1] UZ Brussel, [2] CHU Brugmann, Brussels
- **11:30** C09 **A case of miliary abdominal tuberculosis in an anti-TNF treated patient with Crohn's disease.**
J. Jacobs, L. Pouillon, L. Peperstraete, J. Frans, T. Tollens, P. Bossuyt / Imelda Hospital, Bonheiden
- **11:45** C10 **Mantle cell lymphoma simulating inflammatory bowel disease.**
F. Lifrange, R. De Wind, C. Spilleboudt, A. Van Gossum, P. Demetter / Institut Jules Bordet, Brussels

■ **12:00-14:00** **LUNCH**

THURSDAY 05

■ **13:00-14:00** **BeSPGHAN General Assembly**

13:00-15:00 - SESSION 1

Moderators : P. Bontems (HUDERF Brussels),
B. Hauser (UZ Brussel)

- **14:00** K02 **Post induction infliximab trough levels predict long-term endoscopic remission in paediatric patients with Inflammatory Bowel Disease.**
K. Van Hoeve (1), E. Dreesen (2), I. Hoffman (1), M. Ferrante (1), S. Vermeire (1) / [1] UZ Leuven, [2] KU Leuven
- **14:15** K03 **Detection of Helicobacter pylori in children and adolescents: diagnosis and treatment in Jessa Hospital between 2016 and 2019.**
P. Hiikens, K. Magerman, E. Janssens, L. Waumans, R. Cartuyvels, P. Alliet / Jessa Hospital, Hasselt
- **14:30** K04 **Achalasia or pseudo-achalasia in a 2-year-old boy.**
P. De Bruyne (1), S. Theuns-Valks (2), A. Mubarak (1), L. De Ridder (1), B. De Koning (1), J. Escher (1) / [1] Sophia Children's Hospital - Erasmus MC Rotterdam, NL, [2] Albert Schweitzer Hospital, Dordrecht, NL
- **14:45** K05 **Use of Ustikinumab in an infant with very early onset inflammatory bowel disease: 18 months follow-up.**
B. Hauser, K. Huysentruyt, E. De Greef, G. Veereman, Y. Vandenplas / UZ Brussel

■ **15:00-15:30** **COFFEE BREAK**

- **15:30-17:00** **Invited Lecture: On Boarding Improved Care Now for participating centers.**
R. Colletti and Cincinnati team, USA
K. Shelley (Burlington, USA)



Because patients should be able to
access the medicines they need

biosimilars without borders

A WORLD OF CARE

THURSDAY 05

12:15-13:00

Moderators : L. van Grunsven (UZ Brussel),
A. Jauregui Amezaga (UZ Antwerpen)

- A29 **Curious case of collagenous colitis.**
S. De Meulder (1), F. Van De Mierop (2) / [1] UZ Leuven, [2] Sint Augustinus Ziekenhuis GZA, Antwerp
- I27 **An easy and rapid targeted Next Generation Sequencing-based genotyping assay for the validated IBD risk loci.**
S. Verstockt (1), L. Hannes (1), S. Deman (1), W. Wollants (1), E. Souche (1), B. Verstockt (1), I. Van Der Werf (2), A. Hoischen (3), M. Ferrante (1), S. Vermeire (1), I. Cleynen (1) / [1] KU Leuven, [2] U Antwerpen, [3] Radboud University Medical Center, NDL
- A30 **Adoptive cell transfer of regulatory T cells causes an exacerbation of hepatic steatosis in high-fat high-fructose diet-fed mice.**
M. Van Herck, L. Vonghia, W. Kwanten, T. Vanwolleghe, D. Ebo, P. Michiels, J. De Man, B. De Winter, S. Francque / U Antwerpen
- A31 **The effects of oral valsartan treatment on the increased intrahepatic vascular resistance and disease severity of early NAFLD in rats.**
D. Van Der Graaff (1), W. Kwanten (2), J. De Man (1), B. De Winter (1), P. Michiels (2), S. Francque (2) / [1] U Antwerpen, [2] UZ Antwerpen
- I26 **Increased Endoplasmic Reticulum stress specific chaperones characterise CD fibrosis epithelium tissues and participate to in vitro induction of intestinal fibroblasts differentiation.**
S. Vieujean (1), S. Hu (1), E. Bequet (1), C. Salee (1), C. Massot (1), N. Bletard (1), N. Pierre (1), F. Quesada Calvo (1), D. Baiwir (2), G. Mazzucchelli (2), E. De Pauw (2), P. Delvenne (1), M. Meuwis (1), E. Louis (1) / [1] CHU of Liège [2] ULiège
- A32 **Alterations in bile acids and TGR5 activation in nonalcoholic steatohepatitis.**
J. Gillard (1), A. Tailleux (2), L. Clerboux (3), B. Staels (2), Y. Horsmans (4), L. Bindels (1), I. Leclercq (1) / [1] UCL, Brussels, [2] University of Lille, Inserm, Lille, France, [3] University Hospital of Zurich, Switzerland, [4] UCL Saint-Luc, Brussels

- **A34 Longitudinal characterization of muscle alterations in a rodent model of NASH.**
H. Louvegny (1), M. Nachit (1), C. Bouzin (1), J. Thissen (1), Y. Horsmans (2), G. Vande Velde (3), I. Leclercq (1) / [1] UCL, Brussels, [2] UCL Saint-Luc, Brussels, [3] KU Leuven

- **A35 Discovery of the gut microbial signature driving the efficacy of prebiotic intervention on liver steatosis.**
J. Rodriguez (1), N. Lanthier (1), H. Sophie (1), N. Audrey M. (1), L. Tiphaine (1), P. Sarah A. (1), L. Quentin (1), P. Barbara D. (1), G. Marco A. (2), C. Patrice D. (1), P. Nicolas (2), C. Miriam (3), T. Jean Paul (1), B. Laure B. (1), D. Nathalie M. (1) / [1] UCL, Brussels, [2] ULg Liège, [3] ULB Erasme, Brussels

- **I16 Intestinal fibrosis in Crohn's disease patients is marked by an upregulation of innate immune cells and mucosal B cells.**
B. Creyns (1), G. Dragoni (1), J. Cremer (1), G. Bislenghi (2), B. Verstockt (1), M. Ferrante (1), S. Vermeire (1), G. Van Assche (1), A. D'hoore (2), G. De Hertogh (1), C. Breynaert (2) / [1] KULeuven, [2] UZ Leuven

- **I17 Fibrogenesis in chronic DSS colitis is driven by an innate lymphoid cell-independent innate immune response.**
B. Creyns (1), J. Cremer (1), L. Boon (2), G. De Hertogh (3), M. Ferrante (3), S. Vermeire (3), G. Van Assche (3), J. Ceuppens (1), C. Breynaert (1) / [1] KULeuven, [2] Bioceros, Utrecht, ND, [3] UZ Leuven



**BIOCODEX
MICROBIOTA
FOUNDATION**

BELUX 2020

NATIONAL CALL FOR RESEARCH PROJECTS

❖ **GUT MICROBIOTA IN
HUMAN HEALTH AND DISEASES**

Submission
deadline:
October 31, 2020

Amount
of the grant:
€25.000

Decision of
the National
Scientific
Committee:
January 2021

**Please send the application
form by email to:**
bmfbelux@biocodex.be

Further information available on:
www.BiocodexMicrobiotaFoundation.com

20:30 : GRANTS 2020 - AWARD CEREMONY

BWGE Research Grants:

- **Single-cell atlas of adipose tissue macrophages in non-alcoholic fatty liver disease.**
Markus Boesch, KU Leuven, Laboratory of Hepatology, CHROMETA Department
- **DYSplasia COlorectal BIOmarkers–Dyscobio project.**
Angela-Maria Merli, ULiège, GIGA institute
- **Characterization of orthotopic syngeneic HCC mouse model combined with in vivo bioluminescencemediated tumor growth monitoring.**
Bart Vanderborght, U Ghent, Hepatology Research Unit & Gut-Liver ImmunoPharmacology unit

Acta Gastroenterologica Belgica – Best Belgian Original Manuscript 2019:

- **Hepatitis B virus vaccination and revaccination response in children diagnosed with coeliac disease: a multicentre prospective study.**
Thais Rousseff (Ghent University)

BWGE 2020 Prizes:

- **Best Poster Prize Clinical**
- **Best Poster Prize Basic**
- **Best Case Report**

BASL, BGDO, BIRD, BSGIE, BeSPGHAN, Proctology and Pathology Prizes will be announced but are awarded during their respective sessions.

DINNER & PARTY

FELIX PAKHUIS



VENUE: Felix Pakhuis

Godefriduskaai, 30 – 2000 Antwerp

Time: 7:30 pm *Aperitive*

8:30 pm *Award Ceremony*

8:45 pm *Dinner & Party*

Bus transfers: 7:00 pm *Departure from the Hilton Hotel*

11:00 pm – 12:00 pm – 1:00 am

Departures from Felix Pakhuis

Registration: 35€ for registered participants

80€ for an accompanying person



04 > 06.03.20

BWGE 2020

In conjunction with the BGDO session, Lilly kicks off the BGDO session with 30-min. breakfast meeting during the Belgian Week of Gastroenterology

BREAKFAST MEETING

Lightning talks on aHCC

Addressing the gaps & looking ahead



A 30-minute update consisting of 4 short and dynamic topics, brought to you by:

Prof. Ivan Borbath,
Gastroenterology and
Digestive Oncology,
Cliniques Universitaires
Saint-Luc, Belgium



Prof. Jeroen Dekervel,
Digestive Oncology Unit,
University Hospitals
Leuven, Belgium



Leave on time



Avoid traffic



Enjoy breakfast

FRIDAY MARCH 6TH 2020

**HÔTEL HILTON - ROOM TEUN
GROENPLAATS, 2000 ANVERS**

8h30-9h:

Breakfast will be served as from
8h00 until the end of the session

- 08:30 - 09:00 **Breakfast Symposium ELI LILLY :**
Lightning talks on aHCC. Addressing the gaps & looking ahead.

Speakers: Ivan Borbath (UCL Saint-Luc),
Jeroen Dekervel (UZ Leuven)



09:00-10:30 - SESSION 1 : Best abstracts selected for Oral communications

**Moderators : V. Casneuf (OLV Aalst),
A. Hendlisz (Institut Jules Bordet Brussels)**

- 09:00 001 **Real world incidence of microsatellite instability or EBV positivity in a Belgian cohort of patients with adenocarcinoma of the esophagus, gastroesophageal junction and stomach.**
S. De Meulder, X. Sagaert, P. Nafteux, B. Topal, C. Verslype, S. Tejpar, E. Van Cutsem, J. Dekervel / UZ Leuven
- 09:15 002 **Induction by mFOLFIRINOX followed by stereotaxic body radiotherapy with simultaneous integrated boost (SIB-SBRT) at the tumor-vessel interfaces (TVI) for the neoadjuvant treatment of localized pancreatic cancers.**
C. Bouchart (1), J. Engelholm (1), M. Bali (1), J. Closset (2), J. Navez (2), P. Loi (2), Y. Gökburun (3), T. De Grez (3), A. Hendlisz (1), L. Mans (2), P. Eisendrath (4), D. Van Gestel (1), L. Moretti (1), J. Van Laethem (2) / [1] ULB Bordet, Brussels, [2] ULB Erasme, Brussels, [3] CHR, Namur, [4] ULB Saint-Pierre,
- 09:30 003 **Feasibility and clinical impact of routine molecular testing of gastrointestinal (GI) cancers at a tertiary centre with a multi-gene, next generation sequencing (NGS) panel.**
G. Bregni, T. Sticca, T. Akin Telli, S. Camera, L. Craciun, L. Shaza, A. Deleruelle, M. Anciaux, G. Machiels, A. Deleporte, C. Vandeputte, P. Demetter, D. Larsimont, A. Hendlisz, F. Sclafani / ULB Bordet, Brussels
- 09:45 004 **DNA Methylation Analysis of the PDX1 Gene can be used for PNET Subtyping and has a Possible Prognostic Value.**
G. Boons (1), T. Vandamme (2), J. Ibrahim (1), A. Schepers (1), G. Roeyen (2), A. Driessen (2), C. Blenkiron (3), K. Parker (3), M. Peeters (2), G. Van Camp (1), K. Op De Beek (1) / [1] U Antwerpen, [2] UZ Antwerpen, [3] University of Auckland, New Zealand

- **10:00** O05 **FIGHT-202: A phase 2 study of pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma.**
 E. Van Cutsem (1), A. Vogel (2), V. Sahai (3), A. Hollebecque (4), G. Vaccaro (5), D. Melisi (6), R. Al-Rajabi (7), A. Paulson (8), M. Borad (9), D. Gallinson (10), A. Murphy (11), D. Oh (12), D. Efrat (13), D. Catenacci (14), C. Lihou (15), H. Zhen (15), L. Féliz (15), G. Abou-Alfa (16) / [1] UZ and KU Leuven, [2] Hannover Medical School, Germany, [3] University of Michigan, Ann Arbor, USA, [4] Gustave Roussy, France, [5] Providence Cancer Center Oncology and Hematology Care Clinic, USA, [6] Università degli studi di Verona, , Italy, [7] University of Kansas Cancer Center, USA, [8] Baylor University Medical Center, USA, [9] Mayo Clinic Cancer Center, Rochester, USA, [10] Morristown Memorial Hospital, Carol Cancer Center, USA, [11] Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, USA, [12] Seoul National University Hospital, Seoul, Korea, [13] Fox Chase Cancer Center, USA, [14] University of Chicago Medicine, USA, [15] Incyte Corporation, USA, [16] Memorial Sloan Kettering Cancer Center, USA

- **10:15** O06 **“NEOPAC”: A multi-centric prospective observational registry on the NEOadjuvant therapeutic approach to the localised PAncreatic adenocarcinoma, a collaborative multicentric project (CHU Liège – FLCD – CUSL – ULB Erasme).**
 J. Siple (1), L. Mans (2), M. Figueiredo (2), R. Marechal (2), A. Frère (3), C. Rinken (3), B. Delhougne (3), G. Houbiers (4), C. Hubert (1), J. Closset (2), F. Kreutz (5), H. Kalantari (5), J. Van Laethem (2), D. Van Daele (4), I. Borbath (1) / [1] UCL Saint-Luc, Brussels, [2] ULB Erasme, Brussels, [3] CHR La Citadelle, Liège, [4] CHC, Liège, [5] CHR Verviers

■ **10:30 - 11:00 COFFEE BREAK**

11:00-12:20 - SESSION 2 : Highlights of the year

**Moderators : P. Pauwels (UZ Antwerpen),
E. Van Cutsem (UZ Leuven)**

- **11:00** Highlights of the year: **Upper GI cancers**
 Laura Mans (ULB Erasme, Brussels)

- **11:20** Highlights of the year: **Hepato-Bilio-Pancreatic cancers**
 Jeroen Dekerve (UZ Leuven)

- **11:40** Highlights of the year: **Colo-Rectal cancers**
 Marc Peeters (UZ Antwerpen)

- **12:00** **DPD-flash & BGDO Award**
 Karen Geboes (UZ Gent) & Marc Peeters (BGDO Chairman)

- **12:20** **End of the session**

NASH

PREVALENCE

WILL GROW 63%

BETWEEN 2015 AND 2030¹

**DISCOVER OUR
EDUCATIONAL
MATERIALS ON**

WWW.NASHEDU.COM



¹Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. *Hepatology*. 2018;67(1):123-133.

PURSUING INNOVATIVE THERAPEUTIC & DIAGNOSTIC SOLUTIONS IN METABOLIC & LIVER RELATED DISEASES

TREATMENT

Pursuing
therapeutic
solutions

DIAGNOSTIC

Identifying
patients with
NASH & fibrosis

AWARENESS

Optimizing
standards of care



AN OVERVIEW OF OESOPHAGEAL PATHOLOGY

09:00-10:00 - SESSION 1

Moderators : A. Hoorens (UZ Gent), H. Dano (CUSL)

- **09:00** **Invited Lecture:** Oesophagitis (non-Barrett).
A. Driessen (UZ Antwerpen)
- **09:30** **Invited Lecture:** Dysplasia and submucosal oesophageal lesions: what Gastroenterologists want to know from pathologists?
D. Tate (UZ Gent)

■ 10:00-10:30 COFFEE BREAK

10:30-12:30 - SESSION 2

Moderators : A. Hoorens (UZ Gent), H. Dano (CUSL)

- **10:30** **Invited Lecture:** Pathology of Barrett's oesophagus: from metaplasia to dysplasia and cancer.
M. Jansen (UCL, London, UK)
- **11:15** R01 **Low-grade dysplasia in Barrett's esophagus is downgraded in half of the cases after systematic expert pathology review before patient referral for endoscopic treatment.**
P. Leclercq, G. De Hertogh, R. Bisschops / UZ Leuven
- **11:30** R02 **Subacute liver failure in a pregnant female.**
L. Keulen, N. Gestels, P. Jorens, S. Francque, A. Driessen / UZ Antwerpen
- **11:45** R03 **Actinomycosis of the pancreas: a case report.**
E. Ameloot, F. Berrevoet, P. Hindryckx, J. Boelens, J. Van Dorpe, A. Hoorens / UZ Gent
- **12:00** R04 **An unusual appendiceal mass rises a diagnostic challenge.**
A. Vandendriessche (1), S. Deprez (2), J. Cornille (2), A. Driessen (1) /
[1] UZ Antwerpen, [2] AZ Nikolaas, Sint-Niklaas
- **12:15** R05 **Gastritis: demographic and environmental factors based on a cross-sectional study in Belgium and Bukavu.**
M. Surmont (1), M. Van Gossum (1), A. Philippe (2), A. Nteranya (3), V. Muls (1), M. Nkuize (1), J. Mungwete (3), M. Abedi (3), M. Gomez (2), D. Larsimont (2), T. Serste (1), R. Ntounda (1), J. Mulkay (1), H. Njimi (4), E. Munguakonkwa (3), P. Demetter (5), P. Eisendrath (1), D. Mukwege (3) / [1] ULB Saint-Pierre, Brussels, [2] ULB Bordet, Brussels, [3] Panzi Hospital – UEA , Bukavu, Congo, [4] ULB, Brussels, [5] ULB Saint-Pierre, Brussels

■ 12:30-13:30 LUNCH

13:30-15:00 - SESSION 3

Moderators : A. Driessen (UZ Antwerpen), P. Baldin (CUSL)

- 13:30 **Invited Lecture:** Standardized macroscopic examination for cancer of the oesophagus and oesophagogastric junction.
L. Verset (ULB Bordet)
- 14:00 **Invited Lecture:** Diagnostic criteria and histopathological reporting of malignant epithelial oesophageal tumours.
P. Demetter (ULB Bordet)
- 14:30 **Invited Lecture:** Molecular pathology of oesophageal cancer and its clinical implications.
P. Pauwels (UZ Antwerpen)

■ 15:00-15:30 COFFEE BREAK

15:30-16:30 - SESSION 4

Moderators : A. Driessen (UZ Antwerpen), P. Baldin (CUSL)

- 15:30 R06 **Diagnosing Strongyloides in biopsy specimens: a case report.**
S. Rusu, C. Royer-Chardon, P. Rossignon, G. Verset, V. Huberty, D. Blero, L. Perez-Casanova Gomez, C. Maris, N. D'haene / ULB Erasme, Brussels
- 15:45 R07 **81-year-old man with ulcerated mass in the caecum.**
C. Royer-Chardon, S. Rusu, . Brahimi, L. Mans, N. Bachir, A. Demols, . Simon, L. Perez-Casanova Gomez, C. Maris, . Nortier, N. D'haene / ULB Erasme, Brussels
- 16:00 R08 **Incidence of appendiceal NEN and adherence to pathology classification rules in Belgium.**
S. Ribeiro (1), F. De Maeyer (2), M. De Man (1), S. Carton (3), P. Cuyle (3), T. Vandamme (4), C. Verslype (5), I. Borbath (6), P. Demetter (7), N. Van Damme (8), L. Van Eycken (8), A. Hoorens (9), K. Geboes (1) / [1] UZ Gent, [2] AZ Sint-Elisabeth, Zottegem, [3] Imelda Hospital, Bonheiden, [4] UZ Antwerpen, [5] KU Leuven, [6] UCL, Brussels, [7] ULB Bordet, [8] Belgian Cancer Registry, Brussels, [9] UZ Gent
- 16:15 R09 **Incidence of rectal NEN and adherence to pathology classification rules in Belgium.**
F. De Maeyer (1), M. De Man (2), S. Ribeiro (2), S. Carton (3), P. Cuyle (3), T. Vandamme (4), C. Verslype (5), P. Demetter (6), I. Borbath (7), N. Van Damme (8), L. Van Eycken (8), A. Hoorens (9), K. Geboes (2) / [1] AZ Sint-Elisabeth, Zottegem, [2] UZ Gent, [3] Imeldaziekenhuis, Bonheiden, [4] UZ Antwerpen, [5] UZ Leuven, [6] ULB Bordet, Brussels, [7] UCL Saint-Luc, Brussels, [8] Belgian Cancer Registry, Brussels, [9] UZ Gent
- 16:30 **End of the session**



Live endoscopy from ULB Erasme: demonstration of quality measures for EUS and ERCP and illustration of CBD stone management and chronic pancreatitis management.

Moderators : P. Meier (Hannover, Germany),
R. Bisschops (UZ Leuven),
E. Toussaint (CHU Charleroi)

■ **09:00-10:30 Live demonstrations:**

- D. Blero (ULB Erasme)
- A. Tringali (Roma, Italy)
- P. Eisendrath (ULB Saint-Pierre)
- C. Snauwaert (UCL Saint-Luc, Brussels)

Brief talk between cases: Complication management in ERCP/EUS

Pieter Meier (Hannover, Germany)

Case presentation by BygGIE (Belgian young group of GI Endoscopists)

■ **10:30 - 11:00 COFFEE BREAK**

■ **11:00-12:00 Live demonstrations:**

- D. Blero (ULB Erasme)
- A. Tringali (Roma, Italy)
- P. Eisendrath (ULB Saint-Pierre)
- C. Snauwaert (UCL Saint-Luc, Brussels)

Case presentation by BygGIE (Belgian young group of GI Endoscopists)



PENTAX
MEDICAL

Met gepaste trots kunnen wij u melden dat vanaf 19 november 2019 **PENTAX Medical België** rechtstreeks de distributie van **PENTAX Medical** endoscopie-apparatuur, met de daaraan verbonden service-activiteiten, op zich heeft genomen.

Graag willen wij dit heugelijk feit samen met u vieren door het tonen van een aantal nieuwe productontwikkelingen en het aanbieden van een heerlijke traktatie op onze vernieuwde **PENTAX Medical België** stand.



Interactive Case Report Session: Hepatobiliary diseases

ROOM:
SANCY

09:00-10:15 - SESSION 1

Moderators : A. Geerts (UZ Gent), I. Colle (AZ Aalst, UGent)

- **09:00 C11 Biliary complications in human alveolar echinococcosis: a case report.**
M. Abdessalami, G. Rasschaert, L. Duez, C. Salem, P. Eisendrath, T. Serste /
CHU Saint-Pierre, Brussels
- **09:15 C12 Just another liver cyst (or not!)**
L. Abreu De Carvalho, O. Uyttebroek, A. Vanlander, X. Rogiers, F. Berrevoet /
UZ Gent
- **09:30 C13 Pleural effusion and elevated liver tests: think viral!**
J. Meesters (1), J. Maus (2), S. Naegels (2) / [1] U Antwerpen / UZ Antwerpen,
[2] ZNA Middelheim, Antwerpen
- **09:45 C14 Bile duct stone extraction via PTC rendez-vous assisted single balloon ERCP.**
M. Somers, M. Niekel, S. Bouhadan, A. Jauregui, H. De Schepper, S. Francque,
E. Macken / UZ Antwerpen
- **10:00 C15 Acute grade IV toxic hepatitis due to the e-cigarette.**
G. Van Roey (1), C. Claessens (1), L. Van Tigchelt (1), J. Schouten (2),
W. Verlinden (2), A. Hoorens (3) / [1] AZ TURNHOUT, [2] AZ Nikolaas, Sint-Niklaas,
[3] UZ Gent

■ **10:15-10:45 COFFEE BREAK**

Interactive Case Report Session: Hepatobiliary diseases

ROOM:
SANCY

10:45-12:00 - SESSION 2

Moderators : A. Geerts (UZ Gent), I. Colle (AZ Aalst, UGent)

- **10:45 C16** **Resolution of a Hepatoduodenal fistula after nivolumab treatment in a patient with advanced hepatocellular carcinoma: challenges in immunotherapy.**
T. De Somer, E. Vanderstraeten, V. Bouderez, E. Monsaert, C. Van Steenkiste / AZ Maria Middelaers, Gent
- **11:00 C17** **A rare complication of Lemmel Syndrome: Biliary-Diverticular Fistula From a Duodenal Diverticulum.**
S. Patel, L. Janssens / Mayo Clinic, Rochester, USA
- **11:15 C18** **Dubai took my breath away.**
C. Schoonjans, A. Geerts, H. Degroote, H. Van Vlierberghe, E. Van Braeckel, X. Verhelst / UZ Gent
- **11:30 C19** **Reopening of the native portomesenteric axis after cavoportal hemitransposition in a liver transplant patient.**
M. Clarysse, A. Wilmer, Y. Debaveye, W. Laleman, F. Nevens, S. Van Der Merwe, H. Van Malenstein, M. Sainz-Barriga, D. Monbaliu, J. Pirenne / UZ Leuven
- **11:45 C20** **The use of ribavirin in a severe case of hepatitis E infection necessitating renal replacement therapy.**
M. Staessens, T. Vanwolleghem, L. Vonghia, S. Francque, T. Steinhauser, B. Bracke, L. Roossens, E. Philipse, M. Couttenye, K. Dams / UZ Antwerpen

■ **12:00 - 14:00 LUNCH**

12:15-13:00

Moderators : J.-F. Rahier (UCL Namur), N. Lanthier (UCL Saint-Luc)

- A29 **Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: a long-term observational cohort study.**
Ö. Koc (1), G. Robaey (2), H. Topal (3), R. Bielen (1), D. Busschots (1), J. Fevery (3), G. Koek (4), F. Nevens (3) / [1] Universiteit Hasselt, [2] Ziekenhuis Oost Limburg, Genk [3] UZ Leuven, [4] Maastricht University Medical Centre, Netherlands (the)
- I 31 **The impact of vedolizumab on extra-intestinal manifestations in IBD patients: a real-life experience of a single center cohort.**
M. Truyens (1), J. Geldof (1), G. Dewitte (1), E. Glorieus (1), A. Peeters (1), D. Elewaut (2), G. Varkas (2), T. Lobaton Ortega (1) / [1] UZ Gent, [2] U Gent
- A 38 **Nutritional modulation of the gut-liver-brain axis in alcohol-dependent patients: preliminary results of the Gut2Brain study.**
C. Amadiou, S. Leclercq, A. Neyrinck, P. Stärkel, P. De Timary, N. Delzenne / UCL Brussels
- I 29 **Prognostic and therapeutic long-term outcome of patients with ulcerative proctitis: analysis from a large referral center cohort study.**
E. Dubois, A. Moens, J. Sabino, M. Ferrante, S. Vermeire / UZ Leuven
- A 37 **High accuracy of Controlled Attenuation Parameter and Vibration Controlled Transient Elastography for detection of steatosis and fibrosis respectively in NAFLD.**
J. Weyler, L. Vonghia, W. Verlinden, A. Bagdadi, P. Michielsens, T. Vanwolleghem, A. Driessen, S. Francque / UZ Antwerpen
- I 20 **Single Center Experience of Ustekinumab: Therapeutic Drug Monitoring in Crohn's disease Patients.**
C. Liefverinckx (1), M. Fassin (2), D. Thomas (3), C. Minsart (2), A. Cremer (1), L. Amininejad (1), V. Tafciu (2), V. Wambacq (1), A. Van Gossum (1), D. Franchimont (1) / [1] ULB Erasme, [2] ULB, Brussels, [3] KU Leuven
- G 11 **A multinational retrospective, cohort study of patients with Buried Bumper Syndrome treated endoscopically with a novel dedicated device.**
D. Costa (1), P. Hindryckx (2), E. Despott (1), A. Murino (1) / [1] The Royal Free Hospital and University College London (UCL) Institute for Liver and Digestive Health, UK, [2] UZ Gent
- I 25 **Chronic fatigue in associated with increased disease-specific avoidance in Inflammatory Bowel Disease patients.**
L. Fierens (1), I. Van De Pavert (1), M. Walentynowicz (1), S. Coenen (2), P. Geens (2), E. Weyts (2), L. Van Oudenhove (1), J. Vlaeyen (1), A. Von Leupoldt (1), G. Van Assche (2), S. Vermeire (2), M. Ferrante (2), I. Van Diest (1) / [1] KU Leuven, [2] UZ Leuven
- O 09 **The association between primary tumour location, biomarkers and survival: a Belgian population-based study.**
K. Janssens (1), G. Van Camp (1), E. Franssen (2), K. Op De Beeck (1), N. Van Damme (3), M. Peeters (4) / [1] Center of Medical Genetics, Edegem, [2] U Antwerpen, [3] Belgian Cancer Registry, Brussels, [4] UZ Antwerpen



Together, we have been striving to **advance the standard of care** in inflammatory bowel disease for over **10 years**.

We are committed to creating a brighter future for your patients by connecting **your expertise** and **dedication** with **our innovation**.

Immunology

Gastroenterology
Rheumatology
Dermatology

abbvie

14:00-15:30 - SESSION 1

Moderators : P. Deprez (UCL Saint-Luc),
G. Roeyen (UZ Antwerpen)

- **14:00** **Invited Lecture: Anatomic variations of the bilio-pancreatic ductal system and bilio-pancreatic diseases.**
Myriam Delhayé (ULB Erasme Brussels)

- **14:30** P01 **Feasibility and safety of EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: a prospective evaluation.**
M. Figueiredo Ferreira, C. Bouchart, M. Luigi, L. Mans, Y. Gokburun, T. De Grez, M. Bali, J. Engelholm, J.-L. Van Laethem, P. Eisendrath / ULB Erasme, ULB Institut Jules Bordet, CHR Namur, CHU Saint-Pierre, Brussels

- **14:45** P02 **Long-term safety of indwelling double pigtail stents for drainage of pancreatic collections with disconnected pancreatic duct syndrome.**
P. Gkolfakis, A. Bourguignon, M. Arvanitakis, A. Baudewyns, P. Eisendrath, D. Blero, A. Lemmers, M. Delhayé, J. Devière / ULB Erasme, Brussels; CHU Saint-Pierre, Brussels

- **15:00** P03 **Endoscopic ultrasounded-guided radiofrequency ablation for pancreatic lesions: Belgian experience.**
L. Monino, B. Ivan, P. Hubert, M. Tom, D. Pierre / UCL Saint-Luc, Brussels

- **15:15** P04 **Treatment of a large WON with a novel instrument: the EndoRotor DEN Microdebrider.**
E. Macken, M. Somers, H. de Schepper, A. Jauregui, S. Bouhadan, S. Francque / UZ Antwerpen

■ **15:30 - 16:00** **COFFEE BREAK**

16:00-17:10 - SESSION 2

Moderators : P. Eisendrath (Saint-Pierre, Brussels),
P. Hindryckx (UZ Gent)

- **16:00** **Invited Lecture: New ESGE update on PEP prevention guidelines.**
J.-M. Dumonceau (Hôpital Marie Curie, Charleroi)
- **16:30** P05 **Autoimmune pancreatitis: beware of malignancies.**
C. Dumont, I. Borbath, C. Dragean, M. Komuta, P. Deprez / UCL Saint-Luc, Brussels
- **16:40** P06 **Groove Pancreatitis.**
J. Brant, S. Sweetser / Mayo Clinic, Rochester, USA
- **16:50** P07 **Nivolumab-induced pancreatitis.**
L. Janssens, S. Patel, N. Takahashi, S. Majumder / Mayo Clinic, Rochester, USA
- **17:00** P08 **Opioid related sphincter of Oddi dysfunction causing double duct sign in a patient with gastric bypass.**
C. Salem, C. Musala, G. Rasschaert, L. Duez, T. Serste, P. Eisendrath / CHU Saint-Pierre, Brussels
- **17:10** **End of the session**

HEMORRHOIDAL DISEASE AND SELECTED ABSTRACTS

14:00-16:00

Moderators : M.A. Denis (UCL), A. Kartheuser (UCL)

- **14:00 M01** **Injection of botulinum toxin significantly increases efficiency of fissurectomy in the treatment of chronic anal fissures.**
J. Wyndaele, G. Coremans, P. Roelandt / UZ Leuven
- **14:10 M02** **Anal dysplasia in HIV-seropositive men. Prevalence in the Ghent population.**
E. Gökce (1), J. Van Dorpe (2), A. Hoorens (2), J. Pelgrom (2), F. Van Wanzeele (2), L. Vandekerckhove (2), S. Callens (2), D. De Looze (2) / [1] Ugent, [2] UZ Gent

Postgraduate symposium: Hemorrhoidal disease.

- **14:20** **What is symptomatic hemorrhoidal disease?**
D. De Looze (UZ Gent)
- **14:40** **Invited Lecture: Critical appraisal of (new) interventional techniques in hemorrhoidal disease.**
L. Siproudhis (Rennes, France)
- **15:15** **Summary of the Belgian guidelines in hemorrhoidal disease: conservative treatment.**
H. De Schepper (UZ Antwerpen)
- **15:30** **Summary of the Belgian guidelines in hemorrhoidal disease: surgical treatment.**
D. Vandeputte (UZ Gent)
- **15:45-16:00** **The Belgian Week Proctology Quiz.**
M.A. Denis (UCL Saint-Luc), P. Roelandt (KU Leuven)
- **16:00** **End of the Session**



Swallowing difficulties?

Come and visit us at booth A3



E-Posters

BELLE EPOQUE

BSL-BLIC e-Posters

- A27 **Curative Liver Transplantation for Hemin-Refractory Acute Intermittent Porphyrria: A Tertiary Center Experience.**
M. Bronswijk (1), S. De Cock (2), P. Vermeersch (1), F. D'heygere (3), D. Monbaliu (1), J. Pirenne (1), W. Meersseman (1), D. Cassiman (1) / [1] UZ Leuven, [2] AZ Sint-Lucas Brugge, [3] AZ Groeninge, Kortrijk
- A28 **Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: a long-term observational cohort study.**
Ö. Koc (1), G. Robaey (2), H. Topal (3), R. Bielen (1), D. Busschots (1), J. Fevery (3), G. Koek (4), F. Nevens (3) / [1] Universiteit Hasselt, [2] Ziekenhuis Oost Limburg, Genk [3] UZ Leuven, [4] Maastricht University Medical Centre, Netherlands (the)
- A29 **Defective gut adaptive immunity during early alcoholic liver disease.**
L. Maccioni (1), B. Pirlot (1), I. Leclercq (1), Y. Horsmans (2), B. Schnabl (3), P. Starkel (2) / [1] UCL Brussels, [2] UCL Saint-Luc, Brussels, [3] University of California San Diego, USA
- A30 **Adoptive cell transfer of regulatory T cells causes an exacerbation of hepatic steatosis in high-fat high-fructose diet-fed mice.**
M. Van Herck, L. Vonghia, W. Kwanten, T. Vanwolleghem, D. Ebo, P. Michielsens, J. De Man, B. De Winter, S. Francque / U Antwerpen
- A31 **The effects of oral valsartan treatment on the increased intrahepatic vascular resistance and disease severity of early NAFLD in rats.**
D. Van Der Graaff (1), W. Kwanten (2), J. De Man (1), B. De Winter (1), P. Michielsens (2), S. Francque (2) / [1] U Antwerpen, [2] UZ Antwerpen
- A32 **Alterations in bile acids and TGR5 activation in nonalcoholic steatohepatitis.**
J. Gillard (1), A. Tailleux (2), L. Clerbaux (3), B. Staels (2), Y. Horsmans (4), L. Bindels (1), I. Leclercq (1) / [1] UCL, Brussels, [2] Inserm, Institut Pasteur de Lille, France, [3] University (Hospital) of Zurich, Switzerland, [4] UCL Saint-Luc, Brussels
- A33 **SimBA: a user-friendly high throughput tool for spheroid invasion analysis of hepatocellular carcinoma cell lines.**
E. Van De Vijver, A. Vandierendonck, C. Ampe, M. Van Troys, H. Van Vlierberghes / U Gent
- A34 **Longitudinal characterization of muscle alterations in a rodent model of NASH.**
H. Louvegny (1), M. Nachit (1), C. Bouzin (1), J. Thissen (1), Y. Horsmans (2), G. Vande Velde (3), I. Leclercq (1) / [1] UCLouvain, [2] UCL Saint-Luc, [3] UZ Leuven
- A35 **Discovery of the gut microbial signature driving the efficacy of prebiotic intervention on liver steatosis.**
J. Rodriguez (1), N. Lanthier (1), S. Hiel (1), A.M. Neyrinck (1), T. Le Roy (1), S.A. Potgens (1), Q. Leyrolle (1), B.D. Pachikian (1), M.A. Gianfrancesco (2), P.D. Cani (1), N. Paquot (2), M. Cnop (3), J.P. Thissen (1), L.B. Bindels (1), N.M. Delzenne (1) / [1] UCL, Brussels, [2] U Liège, [3] ULB Bruxelles

- A36 **Carbon nanoparticle C60 fullerene as a treatment of hepatocellular carcinoma.**
H. Kuznietsova (1), N. Dziubenko (1), T. Herheliuk (2), O. Lynchak (1), Y. Prylutsky (1), U. Ritter (3) / [1] Taras Shevchenko National University, Kyiv, Ukraine, [2] Institute for Problems of Cryobiology and Cryomedicine, Kyiv, Ukraine, [3] Technische Universität Ilmenau, Germany
- A37 **High accuracy of Controlled Attenuation Parameter and Vibration Controlled Transient Elastography for detection of steatosis and fibrosis respectively in NAFLD.**
J. Weyler, L. Vonghia, W. Verlinden, A. Bagdadi, P. Michiels, T. Vanwolleghem, A. Driessen, S. Francque / UZ Antwerpen
- A38 **Nutritional modulation of the gut-liver-brain axis in alcohol-dependent patients: preliminary results of the Gut2Brain study.**
C. Amadiou, S. Leclercq, A. Neyrinck, P. Stärkel, P. De Timary, N. Delzenne / UCL Brussels
- A39 **The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus Patients.**
L. Heyens (1), Y. Kockaerts (2), D. Busschots (1), R. Bielen (1), J. Wellens (3), C. Van Steenkiste (3), S. Francque (4), G. Robaey (1) / [1] Universiteit Hasselt, [2] Ziekenhuis Oost Limburg, [3] AZ Maria Middelaars, Ghent, [4] U Antwerpen

General Gastroenterology e-Posters

- GE01 **Clinical audit on effectiveness of Helicobacter pylori treatment in Singapore – A Multiracial Asian Cohort.**
K. Lim (1), A. Tiing Leong (1), K. Andrew Boon Eu (1), A. Daphne (1), T. Eng Kiong (1) / [1] Changi General Hospital, Singapore
- GE02 **Bismuth-based vs. standard triple therapy for the eradication of Helicobacter pylori in Belgium: preliminary results.**
S. François (1), F. Mana (2), R. Saminou (3), V. Lamy (4), S. Cadranet (5), P. Bontems (5), V. Miendje Deyi (3), E. Macken (6), S. Kindt (1) / [1] UZ Brussel, [2] Clinique Saint-Jean, Brussels, [3] ULB Saint-Pierre, Brussels, [4] CHU Charleroi, [5] CHU Brugmann, Brussels, [6] UZ Antwerpen
- GE03 **Inulin-enriched diet as a sustainable dietary approach to modulate psychological health in obese subjects: link with the gut microbiota and metabolic disorders.**
Q. Leyrolle (1), R. Cserjesi (2), S. Hiel (1), M. Gianfrancesco (3), J. Rodriguez (1), P. Daphné (2), L. Bindels (1), M. Mulders (1), G. Zamariola (1), C. Amadiou (1), A. Neyrinck (1), P. Cani (1), N. Lanthier (1), P. Trefois (4), O. Klein (2), O. Luminet (1), N. Paquot (3), M. Cnop (2), J. Thissen (1), N. Delzenne (1) / [1] UCL, Brussels, [2] ULB Brussels, [3] ULg Liège, [4] UCL Saint-Luc, Brussels

E-Posters

BELLE EPOQUE

IBD-BIRD e-Posters

- I 16 **Intestinal fibrosis in Crohn's disease patients is marked by an upregulation of innate immune cells and mucosal B cells.**
 B. Creyns (1), G. Dragoni (1), J. Cremer (1), G. Bislenghi (2), B. Verstockt (1), M. Ferrante (1), S. Vermeire (1), G. Van Assche (1), A. D'hoore (2), G. De Hertogh (1), C. Breynaert (2) / [1] KULeuven, [2] UZ Leuven
- I 17 **Fibrogenesis in chronic DSS colitis is driven by an innate lymphoid cell-independent innate immune response.**
 B. Creyns (1), J. Cremer (1), L. Boon (2), G. De Hertogh (3), M. Ferrante (3), S. Vermeire (3), G. Van Assche (3), J. Ceuppens (1), C. Breynaert (1) / [1] KULeuven, [2] Bioceros, Utrecht, Netherlands (the), [3] UZ Leuven
- I 18 **Proteins citrullination and Crohn's disease: PAD4 but not PAD2 is a strong marker of ileal inflammation.**
 G. Dragoni (1), B. Creyns (1), G. De Hertogh (1), B. Verstockt (1), W. Wollants (1), B. Ke (1), L. Marcellis (1), G. Matteoli (1), A. D'hoore (2), A. Galli (3), M. Ferrante (1), S. Vermeire (1) / [1] KU Leuven, [2] UZ Leuven, [3] University of Florence, Firenze, Italy
- I 19 **Vedolizumab dose optimization: findings from a Belgian registry.**
 E. Louis (1), V. Muls (2), P. Bossuyt (3), A. Colard (4), A. Nakad (5), D. Baert (6), F. Mana (7), P. Caenepeel (8), S. Vanden Branden (9), S. Vermeire (10), F. D'heyghe (11), B. Strubbe (12), A. Cremer (13), J. Coche (14), V. Setakhr (15), F. Baert (16), A. Vijverman (17), J. Coenegrachts (18), F. Flamme (19), A. Hantson (20), K. Wijnen (20), E. Piters (20), P. Dolin (20) / [1] CHU Liege, [2] ULB Saint-Pierre, Brussels, [3] Imeldaziekenhuis, Bonheiden, [4] Hopital CHC Liège, [5] CHwapi Notre Dame, Tournai, [6] Maria Middelaers Medical Centre, Gent, [7] UZ Brussel, [8] Ziekenhuis Oost Limburg, Genk, [9] OnzeLieveVrouwziekenhuis, Aalst, [10] UZ Leuven, [11] AZ Groeninge, Kortrijk, [12] AZ Sint-Lucas, Gent, [13] ULB Erasme, Brussels, [14] Clinique Saint-Pierre, Ottignies, [15] CHU UCL Namur site Sainte Elisabeth, Brussels, [16] AZ Delta, Roeselare, [17] Hospital CHR de la Citadelle, Liège, [18] Jessa Ziekenhuis, Hasselt, [19] CHU Ambroise Paré, Mons, [20] Takeda Belgium, UK and USA
- I 20 **Single Center Experience of Ustekinumab: Therapeutic Drug Monitoring in Crohn's disease Patients.**
 C. Liefverinckx (1), M. Fassin (2), D. Thomas (3), C. Minsart (2), A. Cremer (1), L. Amininejad (1), V. Tafciu (2), V. Wambacq (1), A. Van Gossum (1), D. Franchimont (1) / [1] ULB Erasme, [2] ULB, Brussels, [3] KU Leuven
- I 21 **Prevalence of fatigue in a severe IBD cohort highly exposed to biologics.**
 C. Liefverinckx (1), M. El Hamdi (1), M. Fassin (2), A. Cremer (1), C. Minsart (1), L. Amininejad (1), V. Wambacq (1), A. Van Gossum (1), D. Franchimont (1) / [1] ULB Erasme, [2] ULB, Brussels

- I 22 **Real-world Experience of peri-operative treatments on surgical complications after Ileo-caecal resection in Crohn's disease.**
S. Di Stefano (1), C. Liefverinckx (2), A. Cremer (2), L. Amininejad (2), A. Van Gossum (2), J. Deviere (2), J. Van De Stadt (2), D. Franchimont (2), A. Buggenhout (2) / [1] University of Verona. G.B. Rossi University Hospital, Italy, [2] ULB Erasme, Brussels
- I 23 **Persistence of vedolizumab maintenance therapy: Findings from a Belgian registry.**
E. Louis (1), V. Muls (2), P. Bossuyt (3), A. Colard (4), A. Nakad (5), D. Baert (6), F. Mana (7), P. Caenepeel (8), S. Vanden Branden (9), S. Vermeire (10), F. D'heygere (11), B. Strubbe (12), A. Cremer (13), J. Coche (14), V. Setakhr (15), F. Baert (16), A. Vijverman (17), J. Coenegrachts (18), F. Flamme (19), A. Hantson (20), K. Wijnen (20), E. Pijters (20), G. Hantsbarger (20), P. Dolin (20) / [1] CHU de Liège, [2] ULB Saint-Pierre, Brussels, [3] Imeldaziekenhuis, Bonheiden, [4] Hopital CHC Liège, [5] CHwapi Notre Dame, Tournai, [6] Maria Middelaars Ziekenhuis, Gent, [7] UZ Brussel, [8] Ziekenhuis Oost Limburg, Genk, [9] Onze-Lieve-Vrouw Ziekenhuis, Aalst, [10] UZ Leuven, [11] AZ Groeninge, Kortrijk, [12] AZ St Lucas, Gent, [13] ULB Erasme, Brussels, [14] Clinique Saint-Pierre, Ottignies, [15] CHU UCL Namur site Sainte Elisabeth, Brussels, [16] AZ Delta, Roeselare, [17] Hospital CHR de la Citadelle, Liège, [18] Jessa Ziekenhuis, Hasselt, [19] CHU Ambroise Paré, Mons, [20] Takeda Belgium, UK and USA
- I 24 **Ustekinumab in Crohn's disease: « real-life » data from a monocentric patient's Cohort.**
L. Monin, S. Dubois, S. Vieujeun, C. Reenaers, C. Van Kemseke, P. Latour, D. Van Daele, E. Louis / CHU Liege
- I 25 **Chronic fatigue in associated with increased disease-specific avoidance in Inflammatory Bowel Disease patients.**
L. Fierens (1), I. Van De Pavert (1), M. Walentynowicz (1), S. Coenen (2), P. Geens (2), E. Weyts (2), L. Van Oudenhoove (1), J. Vlaeyen (1), A. Von Leupoldt (1), G. Van Assche (2), S. Vermeire (2), M. Ferrante (2), I. Van Diest (1) / [1] KU Leuven. [2] UZ Leuven
- I 26 **Increased Endoplasmic Reticulum stress specific chaperones characterise CD fibrosis epithelium tissues and participate to in vitro induction of intestinal fibroblasts differentiation.**
S. Vieujeun (1), S. Hu (1), E. Bequet (1), C. Salee (1), C. Massot (1), N. Bletard (1), N. Pierre (1), F. Quesada Calvo (1), D. Baiwir (2), G. Mazzucchelli (2), E. De Pauw (2), P. Delvenne (1), M. Meuwis (1), E. Louis (1) / [1] CHU of Liège, [2] ULg Liège
- I 27 **An easy and rapid targeted Next Generation Sequencing-based genotyping assay for the validated IBD risk loci.**
S. Verstockt (1), L. Hannes (2), S. Deman (2), W. Wollants (1), E. Souche (2), B. Verstockt (1), I. Van Der Werf (3), A. Hoischen (4), M. Ferrante (1), S. Vermeire (1), I. Cleynen (2) / [1] UZ Leuven, [2] KU Leuven, [3] U Antwerpen, [4] Radboud University Medical Center, NL

E-Posters

BELLE EPOQUE

- I 28 **Volatomics in inflammatory bowel disease and irritable bowel syndrome: a systematic review.**
K. Van Malderen (1), J. De Man (1), B. De Winter (1), H. De Schepper (2), K. Lamote (1) / [1] U Antwerpen, [2] UZ Antwerpen
- I 29 **Prognostic and therapeutic long-term outcome of patients with ulcerative proctitis: analysis from a large referral center cohort study.**
E. Dubois, A. Moens, J. Sabino, M. Ferrante, S. Vermeire / UZ Leuven
- I 30 **Effectiveness of ustekinumab in refractory Crohn's Disease: a real life experience in a tertiary referral center.**
M. Truyens, J. Geldof, G. Dewitte, E. Glorieus, A. Peeters, P. Hindryckx, T. Lobaton Ortega / UZ Gent
- I 31 **The impact of vedolizumab on extra-intestinal manifestations in IBD patients: a real-life experience of a single center cohort.**
M. Truyens (1), J. Geldof (1), G. Dewitte (1), E. Glorieus (1), A. Peeters (1), D. Elewaut (2), G. Varkas (2), T. Lobaton Ortega (1) / [1] UZ Gent, [2] U Gent

BSGIE e-Posters

- G11 **A multinational retrospective, cohort study of patients with Buried Bumper Syndrome treated endoscopically with a novel dedicated device.**
D. Costa (1), P. Hindryckx (2), E. Despott (1), A. Murino (1) / [1] The Royal Free Hospital and University College London (UCL) Institute for Liver and Digestive Health, UK, [2] UZ Gent
- G12 **Automated polyp size estimation with deep learning reduces interobserver variability.**
J. Suykens, T. Eelbode, J. Daenen, P. Suetens, F. Maes, R. Bisschops / UZ Leuven
- G13 **EUS-directed transgastric intervention (EDGE) in patients with surgically altered anatomy: monocentric experience.**
L. Monino, T. Moreels, H. Piessevaux, Ph. Deprez / UCL Saint-Luc, Brussels
- G14 **The Real Life Diagnostic Accuracy of Regular Arrangement of Collecting Venules in Detecting H.pylori-negative Patients.**
C. De Bie, E. Dubois, M. Bronswijk, R. Bielen, R. Bisschops / UZ Leuven
- G15 **What matters for your patient during gastrointestinal endoscopy: an exploratory research on patient experience and satisfaction.**
M. Surmont (1), Z. Del Rio (2), L. Skenazi (2), C. Hellemans (2), P. Eisendrath (1) / [1] CHU Saint-Pierre, Brussels, [2] ULB, Brussels

- G16 **ESD for oesophageal squamous cell carcinoma: a European tertiary centre Prospectively collected experience.**
M. Figueiredo Ferreira, A. Bucalau, V. Huberty, L. Verset, C. Maris,
J. Van Laethem, I. El Nakadi, J. Devière, A. Lemmers / ULB Erasme, Bruxelles
- G17 **A new 12-French plastic stent may be an alternative in unresectable distal malignant biliary obstruction.**
Ph. Deprez, T. Moreels, T. Aouattah, H. Piessevaux,
E. Pérez-Cuadrado-Robles / UCL Saint-Luc, Brussels
- G18 **Obstructive complications related to the use of self-expandable metallic stent for the treatment of distal biliary stricture.**
W. Soub Defeu, J. Devière, A. Lemmers / C.U.B. ULB Erasme, Brussels
- G19 **We cannot teach our endoscopists to accurately size polyps: a follow-up on the Oostende polyp sizing study.**
S. Van Langendonck (1), A. Billiet (2), K. Hertveldt (3), M. Cool (3),
G. Lambrecht (3), G. Deboever (3) / [1] UZ Antwerpen, [2] UZ Leuven,
[3] AZ Damiaan
- G20 **Risk Stratification of patients in ER presenting with acute upper gastrointestinal bleed using extended Glasgow Blatchford score.**
D. Krishnan (1), G. Panchakapasan (2), S. Shanmughanathan (2) /
[1] Sree Ramachandra Medical College, India
- G21 **Same day propofol sedation does not impair the completion rate of capsule endoscopy.**
O. De Ronde, T. De Ronde, F. Wuestenberghs / CHU UCL Namur, Site de
Godinne, Yvoir
- G22 **Partially covered metallic stent for treatment of gastric leak after sleeve gastrectomy: a retrospective monocentric experience of 760 consecutive surgical procedures.**
B. Vos, J. Rigaux, S. Evrard / Chirec, Braine-l'Alleud
- G23 **Radiofrequency ablation of Barrett esophagus: post reimbursement experience of a tertiary Belgian hospital.**
S. Ouazzani (1), A. Lemmers (1), N. D'haene (1), L. Verset (2), J. Deviere (1),
P. Eisendrath (3) / [1] ULB Erasme, Brussels, [2] ULB Institut Jules Bordet,
Brussels, [3] ULB Saint-Pierre, Brussels

E-Posters

BELLE EPOQUE

BGDO e-Posters

- O07 **NTRK gene fusions in biliary tract cancers.**
A. Demols, L. Rocq, M. Charry, N. De Nève, A. Verrellen, A. Ramadhan, C. Van Campenhout, S. De Clercq, J. Closset, V. Lucidi, J. Van Laethem, I. Salmon, N. D'haene / CUB ULB Erasme
- O08 **Results of a first panTRK IHC ringtrial.**
K. De Winne (1), L. Sorber (2), S. Lambin (1), L. Keulen (1), G. Broeckx (1), P. Pauwels (1), K. Zwaenepoel (1) / [1] UZ Antwerpen, [2] U Antwerpen
- O09 **The association between primary tumour location, biomarkers and survival: a Belgian population-based study.**
K. Janssens (1), G. Van Camp (1), E. Fransen (2), K. Op De Beeck (1), N. Van Damme (3), M. Peeters (4) / [1] Center of Medical Genetics, Edegem, [2] U Antwerpen, [3] Belgian Cancer Registry, Brussels, [4] UZ Antwerpen
- O10 **Development and External Validation of a Prognostic Model Based on 18F-FDG PET/CT Metabolically Active Tumor Volume and Early Metabolic Response for Outcome Prediction in Metastatic Colorectal Cancer under First or Last Line Treatment.**
E. Woff (1), A. Hendlisz (1), L. Salvatore (2), F. Marmorino (3), D. Genovesi (4), G. Critchi (1), T. Guiot (1), L. Ameye (1), M. Paesmans (1), P. Flamen (1) / [1] ULB Bordet, Brussels, [2] Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, [3] Azienda Ospedaliera Universitaria Pisana, Italy, [4] Fondazione Toscana «Gabriele Monasterio», Pisa, Italy
- O11 **Sarcopenia as a Prognostic Factor in Pancreas Cancer Patients Receiving Nab-Paclitaxel+ Gemcitabine: Preliminary Results of 31 First Patients.**
A. Ram (1), C. Vandeputte (2), A. Hendlisz (2), B. Vos (1) / [1] Chirec, Braine-l'Alleud, [2] ULB Bordet, Brussels
- O12 **Immunotherapy as second-line treatment in grade 3 neuroendocrine carcinomas: A prospective case series from an ENETS Center of Excellence.**
T. Vandamme (1), L. De Backer (1), J. Van Den Brande (1), B. Op De Beeck (1), A. Driessen (1), M. Simoens (2), W. Demey (3), H. Prenen (1), M. Peeters (1), W. Lybaert (4) / [1] UZ Antwerpen, [2] ZNA Jan Palfijn, Merksem, [3] KLINIA, Brasschaat, [4] AZ Nikolaas, Sint-Niklaas
- O13 **Al18F-NOTA-octreotide PET imaging of the somatostatin receptor: Biodistribution, dosimetry and first comparison with 68Ga-DOTATATE in neuroendocrine tumour patients.**
E. Pauwels, F. Cleeren, T. Tshibangu, M. Koole, K. Serdons, J. Dekervel, E. Van Cutsem, C. Verslype, K. Van Laere, G. Bormans, C. Deroose / UZ Leuven
- O14 **Treatment management of rectal neuroendocrine neoplasms in Belgium.**
F. De Maeyer (1), M. De Man (2), S. Ribeiro (2), S. Carton (3), P. Cuyle (3), T. Vandamme (4), C. Verslype (5), P. Demetter (6), I. Borbath (7), N. Van Damme (8), L. Van Eycken (8), A. Hoorens (2), K. Geboes (2) / [1] AZ Sint-Elisabeth, Zottegem, [2] UZ Gent, [3] Imeldaziekenhuis, Bonheiden, [4] UZ Antwerpen, [5] UZ Leuven, [6] ULB Bordet, Brussels, [7] UCL Saint-Luc, Brussels, [8] Belgian Cancer Registry, Brussels

- O15 **Treatment of appendiceal neuroendocrine neoplasms in Belgium.**
 S. Ribeiro (1), F. De Maeyer (2), M. De Man (1), S. Carton (3), P. Cuyle (3), T. Vandamme (4), C. Verslype (5), I. Borbath (6), P. Demetter (7), N. Van Damme (8), L. Van Eycken (8), A. Hoorens (1), K. Geboes (1) / [1] UZ Gent, [2] AZ Sint-Elisabeth, Zottegem, [3] Imelda Hospital, Bonheiden, [4] UZ Antwerpen, [5] UZ Leuven, [6] UCL Saint-Luc, Brussels, [7] ULB Bordet, Brussels, [8] Belgian Cancer Registry, Brussels
- O16 **Comparison of digestive and non-digestive neuroendocrine neoplasm patient characteristics and survival in an ENETS Center of Excellence.**
 T. Vandamme (1), L. De Backer (1), I. Dero (2), D. Galdermans (3), P. Abrams (4), T. Rondou (5), M. Ulenaers (6), C. Mattelaer (3), M. Peeters (1), W. Lybaert (7) / [1] U Antwerpen / UZ Antwerpen, [2] Sint Augustinus Ziekenhuis GZA, Antwerpen, [3] ZNA Middelheim, Antwerpen, [4] GZA Sint-Vincentius ziekenhuis, Antwerpen, [5] AZ Rivierenland, Bornem, [6] AZ Rivierenland, Rumst, [7] AZ Nikolaas, Sint-Niklaas
- O17 **Efficacy and Safety of Lanreotide Autogel 120 mg (LAN 120 mg) in the Treatment Of Clinical Symptoms Associated with Inoperable Malignant Intestinal Obstruction (IMIO).**
 L. Duck (1), G. Demolin (2), L. D'hondt (3), C. Dopchie (4), K. Hendrickx (5), B. Lannoye (6), F. Bastin (7), D. Lossignol (8), O. Hamdan (9), V. Vandenhoute (10), W. Lybaert (11), V. De Ruyter (12), B. Regnault (13), K. Geboes (14) / [1] Clinique Saint-Pierre, Ottignies, [2] CHC, Liège, [3] CHU-UCL-Namur site Godinne, Yvoir, [4] Centre Hospitalier de Wallonie Picarde, Tournai, [5] OLV Aalst, [6] Vivalia Libramont, [7] CHR Verviers, [8] ULB Bordet, Brussels, [9] CSF Chimay, [10] Cliniques de l'Europe Site Sainte-Elisabeth, Brussels, [11] AZ Nikolaas, Sint-Niklaas, [12] IPSSEN NV, Merelbeke, [13] Ipsen, Boulogne-Billancourt, France, [14] UZ Gent
- O18 **Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Outcomes by Prior Locoregional and Prior Sorafenib treatment from REACH and REACH-2.**
 I. Borbath (1), J. Llovet (2), E. Assenat (3), B. Daniele (4), C. Wang (5), R. Widau (6), K. Buelens (6), I. Nitu (6), A. Zhu (7) / [1] UCL Saint-Luc, Brussels, [2] Mount Sinai School of Medicine, New York, USA, [3] St-Eloi University Hospital, Montpellier, France, [4] Azienda Ospedaliera G. Rummo, Benevento, Italy, [5] Eli Lilly and Company, Indianapolis, USA, [6] Eli Lilly and Company, Indianapolis, USA, [7] Massachusetts General Hospital, Boston, USA

WEDNESDAY 04

Belgian Week of
Gastroenterology
asbl / vzw

THURSDAY 05

SAVE THE DATE

03 > 05 . 03 . 2021



www.bwge.be

We discover, develop and deliver innovative medicines that help people prevail over serious diseases.

We are committed to address the unmet medical needs of patients in the areas of

IMMUNO-ONCOLOGY

CARDIOVASCULAR



FIBROSIS



IMMUNOSCIENCE



ONCOLOGY



Visit www.bms.com/be - www.bms.com/lu

To learn more about our commitment
to patients in Belgium and Luxembourg

Notes



Our dedication today, is to give her
the promise of a tomorrow.

Maria, cancer patient.



BEN 20 ONC 11 SB GS 01 - Date of medical approval 17/01/2020.

Servier Oncology: Delivering better tomorrows together.

Lonsurf[®]
trifluridine/tipiracil

 **onivyde**[®]
liposomal irinotecan

With the Kind Support of our Partners,
BWGE becomes possible! THANK YOU

PLATINUM



GOLD

abbvie



Lilly



SILVER

ACTA GASTROENTEROLOGICA • ALNYLAM •
BOSTON SCIENTIFIC • EISAI • MEAD JOHNSON • NORGINE •
OLYMPUS • ONIS • RECKITT BENKISER • SANDOZ • SERVIER

BRONZE

AMGEN • ARKOPHARMA • BIOCODEX • BMS • BOUCART MEDICAL • COOK MEDICAL •
DE GROOF-PETERCAM • DR FALK PHARMA • ECCE MEDICAL • ECHOSENS •
ERBE BELGIUM • FRESENIUS-KABI • GE HEALTHCARE • GENFIT • GMP-ORPHAN •
INCYTE • IPSEN • LABORIE • LAMEPRO • MEDIQUALITY • NESTLE HEALTH SCIENCE •
NESTLE NUTRITION • REVOGAN • RVC • SIEMENS • SIRTEX • TILMAN • TRUVION MEDICAL •
VIFOR PHARMA • VIVIO • Wassenburg Medical • WORLD SCIENTIFIC PUBLISHING

ULTRA SOUND COURSE

GE HEALTHCARE • SIEMENS

ASSOCIATIONS

BVT • F.A.P.A. • CHAC • Chrohn FR • Chrohn NL • GBS-VBS • Gent Endoscopy meeting • VIB Grand Challenges

XXXIInd Edition – Hilton Antwerp – 04 > 06.03.20

BWGE Event Coordination : DME Events • Anne-France De Meyer • 57 av. G Demey 1160 Bruxelles •
anne.france.de.meyer@dme-events.eu • Tel : 0477 27 00 45

www.bwge.be